


FROM NATURE TO GLOBAL NUTRITION
GROWING TOGETHER



ANNUAL REPORT
2024-2025



INDEX

- 
- 
- 01 **About Us**
 - 02 **From Nature to Global Nutrition
Growing Together**
 - 03 **Statement from
the Management's Desk**
 - 04 **Nutraceutical
Industry overview**
 - 05 **Value Creation Model**
 - 06 **Core strengths
and differentiators**
 - 07 **Certifications
and Accreditations**
 - 08 **Strategic Experts**
 - 09 **Directors' Report I**
 - 10 **Financial Statements**
 - 11 **Notice**
 - 12 **Corporate Information**



ABOUT US

Accretion Nutraveda Limited

The Company was originally incorporated as **“Accretion Nutraveda Private Limited”**, as a private limited company, under the provisions of the Companies Act, 2013 pursuant to certificate of incorporation dated 16 March, 2021. Our Company converted into **“Accretion Nutraveda Limited”**, a public limited company vide fresh certificate of incorporation dated 02 May, 2025.

Accretion Nutraveda Limited is an Ahmedabad based, healthcare focused company specialising in contract manufacturing. Since its inception in 2021, the Company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries.

The Company is engaged in offering our clients with a quality range of herbal and ayurvedic products in the form of tablets, capsules, liquid orals, oral powders, soft gelatine, external preparations, and oils. The company caters to diverse healthcare segments including Ayurvedic products i.e. Bone & Joint Care, Respiratory Care, Gynec Care, Skin Care, Hair Care, Digestive Care, Urinary Track Care. We have various formulation of Nutraceuticals & Health Supplements for Memory & Neuron Care, Cardiac Care, UTI Care, Liver Care, Paediatric Care, GIT Care etc. Apart from this we manufacture products like various Balm and Oils.

The Company operates manufacturing facility located in Sanand, Ahmedabad, Gujarat, India spans a built-up area of approximately 10,763 sq. ft., strategically positioned within Gujarat's industrial ecosystem. Purpose-built for herbal and nutraceutical production, the plant integrates modern infrastructure with stringent quality protocols to meet evolving market demands. This facility is certified to international quality standards, including GMP (Good Manufacturing Practice), ISO 9001:2015, ISO 45001:2018, Halal certifications and WHO-GMP, ensuring adherence to the highest standards of safety, quality and regulatory compliance.

Our Company is being managed and guided by a visionary team of six seasoned promoters and directors:



Mr. Mayur Popatlal Sojitra



Mr. Harshad Nanubhai Rathod



Mr. Ankurkumar Shantilal Patel



Mr. Paraskumar Vinubhai Parmar



Mr. Vivek Ashok Kumar Patel



Mr. Hardik Mulundbhai Prajapati

Each member of our team brings deep expertise in herbal sciences, nutraceutical formulation, and wellness-driven product development. With strong academic backgrounds in pharmaceutical sciences and hands-on experience spanning R&D, GMP compliance, and market expansion, our team has laid a solid foundation for sustainable growth. Their unwavering focus on innovation, product purity, and consumer trust has enabled the company to establish a distinct presence in the fast-evolving natural health and wellness sector.

FROM NATURE TO GLOBAL NUTRITION
GROWING TOGETHER

“

We stand at the intersection of **ancient Ayurvedic wisdom and cutting-edge nutraceutical science.**

At the heart of Ayurveda lies the belief that nature holds the key to true health and wellness. We begin with pure, natural ingredients, deeply rooted in ancient Ayurvedic wisdom, and transform them into effective, scientifically backed nutritional solutions for people around the world.

We transform this natural wisdom into modern nutritional solutions by integrating Ayurvedic principles with advanced research, technology, and global quality standards. Our products are trusted by consumers across continents seeking natural alternatives for immunity, wellness, and preventive health.

Together, we are building a healthier, more balanced world — **rooted in nature, guided by Ayurveda, and driven by a global mission.**

”



Statement From The Management's Desk

Dear Esteemed Stakeholders,

In an age where health and wellness have become central to our daily lives, the line between food and medicine continues to blur. Today, people are no longer seeking nutrition alone — they are seeking food that heals, strengthens, and prevents. This is the foundation on which the nutraceutical sector is growing, and it is precisely where our work begins.

Accretion Nutraveda Limited stands as one of the most promising and fast-rising names in the healthcare space, delivering high-quality wellness through Ayurveda and Nutraceuticals. Backed by a rich legacy and deep scientific expertise, our commitment is to offer innovative, effective, and accessible health solutions to the world.

The Company serves large-scale corporate clients and emerging specialty brands with dedication, providing custom manufacturing and private-label solutions tailored to the herbal and nutritional supplements market.

With long-standing relationships across our customer and vendor networks, we bring deep industry insight, cutting-edge ingredient science, and efficient manufacturing technologies to every product we develop. What sets us apart is not just the scale of our operations, but the uncompromising quality and service we deliver at every step.

Our vision is clear: to become a leading force in the herbal and nutritional supplements industry by providing value-driven, science-backed, and customer-focused solutions. Every step we take is guided by our commitment to quality, innovation, and customer satisfaction — values that define who we are and where we are headed.

Health is not a destination — it's a journey. And we are proud to walk this journey hand in hand with our stakeholders, customers, and communities. The future of wellness is bright, and we are honored to help shape it.

With warm regards,
Accretion Nutraveda' Team


NUTRACEUTICAL INDUSTRY OVERVIEW

The nutraceutical market in India has seen a significant expansion since 2020, with the emergence of products such as ashwagandha and herbal kaadha, which are designed to promote strong immunity.


In 2021, Bio-Botanical Inc. produced an herbal supplement, designated as “Ashwagandha 5404ST”, to preserve and enhance the skin's health. This herbal supplement can be utilized for a variety of purposes, including skin care, mental health support, and immunological enhancement. Products like herbal honey or chwyawanprash have become a huge success as they are extensively used in jams, chocolates, cheesecakes and capsules as a general health supplement. For instance, in Aril 2021, Amway, the parent company of the renowned Nutrilite brand, declared the official launch of chwyawanprash, a high-quality blend of 32 herbs that have been verified through DNA fingerprinting. The blend is composed of 16 certified organic components and does not contain preservatives. Motivated by traditional Indian recipes, the main purpose of Nutrilite Chwyawanprash is to boost immunity, rejuvenate the body, increase strength, and endurance besides fight common infections. Additionally, in April 2018, Amway India, country's one of the leading direct-selling FMCG company launched its Nutrilite Traditional Herbs range. This range was specifically developed using Indian traditional herbs keeping in mind the nutritional requirements of Indian consumers.

Consequently, contemporary dietary habits are disrupting the attainment of balanced nutrition. This disparity in nutrient consumption is resulting in what was once considered a normal lifestyle becoming increasingly abnormal. Nevertheless, the rise in the affluent working population, coupled with shifting lifestyles and the escalating costs associated with healthcare, both in terms of time and finances, are compelling individuals to reconsider their approach to well-being. Manufacturing nutraceuticals is a multifaceted process with numerous intricacies. To guarantee adherence to standards and maximize safety, it's essential to devise a comprehensive plan spanning from initial research to production. While meticulous attention is necessary at every stage, certain junctures within the production process hold greater significance. Choices regarding raw materials, sourcing strategies, and implementation of controls significantly influence the success of the final product. Whether launching a new nutraceutical or enhancing an existing one, several crucial factors merit consideration before commencing. While each manufacturer has distinct processes and protocols, understanding these tasks is imperative before starting a project.





The quality of raw materials and components plays a pivotal role in determining the excellence of the end product. Manufacturers must prioritize the utilization of top-tier materials to ensure superior outcomes. For instance, when incorporating herbal ingredients into a nutraceutical, opting for pure, uncontaminated herbs devoid of impurities is imperative. Similarly, for minerals, vitamins, oils, and other constituents, sourcing from authentic, high-quality suppliers is crucial.




Source: ASSOCHAM- *Unlocking the Potential of Nutraceuticals (2024)*

Exploring India's Growing Nutraceutical Market: Drivers and Challenges – India Nutraceutical Market

The India nutraceuticals market stood at USD 6,113.20 million in 2023 and is expected to register a CAGR of 11.39% and reach USD 11,800.11 million by 2029. The rising consumer awareness regarding health and sedentary lifestyle-associated issues, growing awareness for nutraceutical benefits, and growing consumer preference towards plant-based and organic health supplements are some of the major trends in the Indian nutraceuticals market. Additionally, rising consumer focus towards preventive healthcare is another primary trend propelling the nutraceuticals industry's growth in the country. The market is hampered by factors, such as the growing adoption of ayurvedic formulas for health and immunity boosts, the high cost of branded nutraceuticals, and the lack of stringent regulatory policies for nutraceuticals. Moreover, the availability of several look-a-like products with fake ingredients in the nutraceutical market is affecting the consumer trust and thus, hindering the market growth. The Indian government has implemented policies and regulations such as the 'Make in India' campaign and the establishment of the Food Safety and Standard Authority of India (FSSAI) to promote the nutraceutical industries and to build the quality, safety, and standards of nutraceutical products.

India Nutraceuticals Market Size, By Value (USD Million), 2019–2029F



Source: ASSOCHAM- *Unlocking the Potential of Nutraceuticals (2024)*

CURRENT REGULATORY FRAMEWORK FOR NUTRACEUTICALS IN INDIA



India is the second-largest producer of fruits and vegetables; however, it is lagging in terms of processing these food products. The term 'nutraceuticals' did not appear in the Indian regulatory framework for food products until 2015. The draft regulations for Health Supplements and Nutraceuticals were made available to the public on 11 September 2015 and were officially notified in the Gazette of India in 2016.

Under these regulations for nutraceuticals and health supplements:

1. In-depth definitions of all categories of functional foods were laid down as per their content and use.
2. The criteria for acceptance of safety, efficacy, and health claims of these products were specified.
3. A list of approved ingredients and excipients was provided to manufacturers, along with the minimum and maximum permissible levels.
4. Requirements relating to quality, labeling, and packaging of nutraceuticals and health supplements were clearly defined.



After the introduction of these regulations in 2016, FSSAI granted one year to food product manufacturers in India to achieve compliance. Accordingly, the effective date of implementation was finalized as 01 January 2018.

Since these regulations have only recently come into force, their impact on the quality of nutraceutical products and on the Indian nutraceutical market is still evolving and yet to be fully observed.

VALUE CREATION MODEL

OUR PRODUCTS

Accretion Nutraveda Limited offers a broad and diversified product portfolio across multiple dosage forms, developed using both classical Ayurvedic formulations and modern nutraceutical science.

The Company's products are manufactured at our GMP-certified facility, ensuring adherence to stringent quality protocols and applicable regulatory standards. Designed to address both preventive and therapeutic healthcare needs, the product range is marketed across domestic and select international geographies.

TABLETS

Tablets: The Company manufactures a broad spectrum of herbal, mineral, and nutraceutical tablets utilizing advanced compression technologies. This product category encompasses classical Ayurvedic formulations as well as standardized herbal extracts, developed to address key health segments including immune support, digestive wellness, joint and bone health, metabolic regulation, and cognitive enhancement.

FORMULATION TYPES

- Film-Coated Tablets
- Uncoated Tablets
- Chewable Tablets
- Effervescent Tablets

THERAPEUTIC CATEGORIES

- Liver Tonic Tablets (e.g., Kalmegh, Bhumiamalaki)
- Gynecological Care (e.g., Ashoka, Lodhra)
- Digestive Enzymes & Antacids (e.g., Triphala, Amlapittahar)
- Bone & Joint Health (e.g., Shallaki, Asthiposhak)
- Respiratory Care (e.g., Sitopaladi)
- Urinary Tract Support (e.g., Punarnava, Gokshura)
- Aphrodisiac & Vitality (e.g., Shilajit, Safed Musli)
- Multivitamin-Mineral Combinations
- Immunity Boosters (e.g., Giloy, Amla + Zinc)
- Brain Tonic Tablets (e.g., Brahmi, Shankpushpi)
- Pain Relief (e.g., Vatari Guggulu)
- Organ-Specific Support (e.g., Cardiac, Hepatic)

CAPSULES

Capsules: The Company's capsule portfolio comprises both hard gelatine and vegetarian (HPMC) capsules, offered in powder-filled and granule-filled formats. These formulations are developed to enhance bioavailability, improve patient compliance, and deliver targeted therapeutic benefits across key health categories

FORMULATION TYPES

- Hard Gelatin Capsules (Powder-Filled)
- HPMC (Vegetarian) Capsules
- Granule-Filled Capsules

THERAPEUTIC CATEGORIES

- Liver Detoxification (e.g., Kutki, Kalmegh)
- Women's Health (e.g., Shatavari, Dashmool)
- Urinary Tract and Kidney Support
- Bone & Joint Care (e.g., Curcumin + Boswellia)
- Aphrodisiac & Energy Enhancers (e.g., Maca, Shilajit)
- Herbal Multivitamins
- Skin & Hair Care (e.g., Biotin, Bhringraj)
- Brain & Cognitive Support (e.g., Bacopa, Malkangani)
- Immune Modulation (e.g., Tinospora, Spirulina)
- Protein & Superfood Capsules (e.g., Moringa, Whey Blend)

ORAL LIQUIDS

Oral Liquids: The Company manufactures a range of high-quality oral liquid formulations, including syrups, tonics, decoctions (kadha), and suspensions. These products are developed to ensure enhanced palatability, formulation stability, and therapeutic efficacy, with particular suitability for paediatric and geriatric segments

FORMULATION TYPES

- Syrups
- Suspensions
- Tonics
- Decoctions (Kadha)

THERAPEUTIC CATEGORIES

- Liver Tonics (e.g., Bhringraj, Kalmegh)
- Digestive Syrups (e.g., Jeera, Pudina, Fennel-based)
- Respiratory Support (e.g., Tulsi, Vasaka, Yashtimadhu)
- Uterine Health (e.g., Ashoka, Lodhra, Dashmool)
- Urinary Support (e.g., Gokshura, Punarnava)
- Brain Tonics (e.g., Brahmi, Mandukparni)
- Baby Care Syrups (e.g., Herbal Gripe Water)
- Immunity Boosters (e.g., Ayush Kwath, Amla Syrup)
- Herbal Multivitamin Syrups

ORAL POWDERS / CHURANS (ORAL HERBAL POWDERS)

Oral Powders / Churans (Oral Herbal Powders) The Company manufactures oral powders, commonly referred to as Churans, formulated using single-ingredient and polyherbal compositions. Rooted in traditional Ayurvedic practices, these products are primarily intended to support digestive health, facilitate detoxification, and promote general wellness.

FORMULATION TYPES

- Single-Herb Powders
- Polyherbal Classical Churans
- Condition-Specific Herbal Blends
- Fortified Nutraceutical Powders

THERAPEUTIC CATEGORIES

- Triphala Churan (Digestive Cleanser)
- Hingwashtak Churan (Gas, Bloating)
- Avipattikar Churan (Acidity Relief)
- Lavan Bhaskar Churan (Appetizer)
- Herbal Protein Blends (Ashwagandha, Moringa-based)
- Superfood Churans (Wheatgrass, Spirulina)
- Multivitamin Powders
- Oral Rehydration Powders (ORS)

OILS

The Company manufactures classical and contemporary herbal oils utilizing traditional Ayurvedic processes such as Taila Paka Vidhi. These oils are formulated for external therapeutic use, with applications across musculoskeletal disorders, dermatological conditions, and paediatric wellness, including massage therapies.

FORMULATION TYPES

- Classical Taila (Medicated Oils)
- Cold-Pressed Herbal Oils

THERAPEUTIC CATEGORIES

- Joint and Muscular Pain Relief (e.g., Mahanarayan, Vishgarbha Taila)
- Hair & Scalp Care (e.g., Bhringraj, Amla)
- Baby Massage Oils (e.g., Bala Taila, Dasmooladi Taila)
- Skin Rejuvenation (e.g., Kumkumadi Taila)

EXTERNAL PREPARATIONS

i) Balms: The Company's external-use product portfolio prominently features balms manufactured using both classical Ayurvedic techniques and modern formulation methods. These products are intended for topical therapeutic application, with key use cases in musculoskeletal relief, dermatological care, and paediatric wellness, including massage therapies.

FORMULATION TYPES

- Pain Relief Balms
- Aromatic Herbal Balms
- Herbal Inhaler

THERAPEUTIC CATEGORIES

- Joint and Muscular Pain Relief
- Balms for Cold, Congestion & Headache

ii) Others The Company's external-use product portfolio also includes creams, ointments, lotions, gels, and herbal cosmetic formulations developed using herbal actives and essential oils. These products are designed to address a range of skin, hair, and pain-related concerns, combining traditional Ayurvedic principles with modern dermatological and therapeutic applications.

FORMULATION TYPES

- Herbal Creams and Ointments
- Topical Gels
- Lotions & Serums
- Face Packs and Herbal Masks
- Herbal Shampoo

THERAPEUTIC CATEGORIES


- Pain Relief Gels (e.g., Gandhapura, Menthol-based)
- Anti-Acne and Antiseptic Creams (e.g., Neem, Aloe Vera)
- Hair Growth Serums (e.g., Bhringraj + Biotin)
- Baby Skin Creams (e.g., Diaper Rash Relief)
- Skin Glow and Hydration (e.g., Saffron, Sandalwood)



TABLETS



**Calcium L Methylfolate Calcium Vitamin B12
Pyridoxine-5-Phosphate Vitamin D3 Tablets**



Female Infertility Tabs



**Glucosamine Sulfate, Chondroitin
Sulfate Msm, & Zinc Tablets**



Iron Tablets




Joint Pain Tablets




Multivitamin Tabs

CAPSULES



Iron folic Vitamin b12 capsules




Piles Capsules Inner



Shilajit Capsules



Slimiz Capsules Label



Vitamin B Complex Capsules

ORAL LIQUID



Digestive Syrup 200ml



Dried Ivy Leaf Extract Cough Syrup



Feminine Tonic Syrup



Gripe Water



Immunity Booster Syrup



Iron Tonic Syrup


ORAL LIQUID




Liver Tonic Junior




LiverTonic Syrup



Lycopene Syrup



Multivitamin Syrup



Vitamin d drops

EXTERNAL PREPARATION



Body Pain Balm



Breast Enhancement Cream



Butt Enhancement Cream



Hair Oil



Headache Balm



Herbal cream 30g

EXTERNAL PREPARATION



Inhaler



Joint Pain Balm



Joint Pain Relief Oil



Pain Relief Balm



Pain Relief Gel



Pain Relief Rollon

EXTERNAL PREPARATION



Vaginal Cream



Joint Pain Balm

CORE STRENGTHS AND DIFFERENTIATORS

COMPETENT LEADERSHIP

The Company is guided by a seasoned and capable management team with deep industry experience. The Promoters, who shape the strategic direction, bring domain expertise closely aligned with the business and are actively involved in both high-level decision-making and daily operations. The Company firmly believes that its skilled, motivated, and experienced workforce is essential to maintaining its competitive edge and achieving long-term goals.

THERAPEUTICALLY DIVERSE PORTFOLIO

The Company is dedicated to delivering high-quality healthcare solutions that meet global standards and align with client expectations. Driven by a vision to offer world-class formulations at competitive prices, the Company has continually expanded its product portfolio to address evolving market needs. With a diverse range of offerings across multiple therapeutic categories, the Company serves a broad and growing customer base in both domestic and international markets.

QUALITY-DRIVEN OPERATIONS

Quality is a cornerstone of the Company's operational philosophy and a fundamental driver of its long-term success. The Company is firmly committed to delivering products that meet stringent quality benchmarks and comply with global standards at every stage of the production process. Our ongoing efforts to enhance manufacturing practices and quality control systems are reflected in key certifications, including ISO 9001:2015 for quality management and ISO 45001:2018 for occupational health and safety management. These accreditations underscore our alignment with internationally recognized protocols for product integrity, safety, and sustainability.



CORE STRENGTHS AND DIFFERENTIATORS

STRONG CLIENT AND SUPPLIER ALLIANCES

The Company has cultivated enduring relationships with its clients and suppliers, which serve as a critical foundation for its business operations. Through transparent communication, reliable service delivery, and collaborative growth initiatives, the Company consistently invests in strengthening these partnerships. Our sales and marketing functions are led by our Promoters, who bring extensive experience and deep industry insight. Their leadership has been pivotal in fostering trust-based relationships across the value chain, driving enhanced customer retention and supplier reliability.

ESTABLISHED PROCESS MECHANISMS

The Company has built a resilient business foundation through well-established operational processes and a trusted management framework. It has guided by management's deep industry experience and strategic foresight, the Company maintains operational stability, ensures timely delivery, and upholds service excellence. This legacy of disciplined execution and stakeholder trust continues to drive growth and reinforces the Company's reputation in both domestic and international markets.



CERTIFICATIONS AND ACCREDITATIONS

The company's certifications demonstrate our unwavering commitment to the highest standards of safety, quality, and regulatory compliance. With advanced machinery, a dedicated quality control department, and a skilled workforce, our facilities are equipped to efficiently and effectively meet the diverse needs of our customers.

Sr. No.	Accreditations & Certifications	Certificate No	Issuing Authority	Date of Issue	Date of Expiry
1.	*Certificate for Good Manufacturing Practices (GMP) to manufacturer Ayurveda, Siddha & Unani Drugs Legal Metrology (Packaged Commodities), Rules 2011 as Manufacturer & Packers	RCMC/SHEFEXIL/00855/2025-2026	Commissioner, Food & Drugs Control Administration, Gandhinagar, Gujrat	01 September, 2021	24 August, 2026
2.	Legal Metrology (Packaged Commodities), Rules 2011 as Manufacturer & Packers	GOI/GJ/2025/5216	Director, Legal Metrology, Department of Consumer Affairs, Ministry of Consumer Affairs, Food and Public Distribution, Government of India	28 July, 2025	-
3.	Food Safety System Certification (FSSC) 22000	SR/4049658/2025	Star Certifications UK	11 July, 2025	10 July, 2028
4.	Halal Certification Scheme	SR/4050897/2025	Star Certifications UK	11 July, 2025	10 July, 2028
5.	ISO 9001:2015 for Quality Management Systems	IN/79017064/6537	ICV Assessments Pvt Ltd.	04 March, 2025	03 March, 2028
6.	ISO 45001:2018 for Occupational Health & Safety Management Systems	IN/84317065/8467	ICV Assessments Pvt Ltd.	04 March, 2025	03 March, 2028
7.	WHO-GMP	SR/3785468/2025	Star Certifications UK	11 April, 2025	10 April, 2028
8.	Food Safety and Standards Authority of India (FSSAI)	10721999000977	Central Licensing Authority, Food Safety & Standards Authority of India	20 August, 2025	05 November, 2029
9.	Registration - cum - Membership Certificate	RCMC/SHEFEXIL/00855/2025-2026	Shellac & Forest Products Export Promotion Council	08 September, 2025	31 March, 2026



BOARD OF DIRECTORS OUR STRATEGIC EXPERTS



MAYUR POPATLAL SOJITRA
Promoter and Director

With a Bachelor's degree of Pharmacy from Gujarat University and an MBA in International Business from the University of Greenwich, London. With over 13 years of experience in the healthcare industry, he has been associated with the group since long and currently leads Accretion Nutraveda Limited. Under his leadership, the Company has leveraged his strong technical expertise, global business acumen, and result-oriented approach to translate innovative ideas into successful ventures, ensuring sustainable growth and diversification.



ANKURKUMAR SHANTILAL PATEL
Promoter and Director

With Bachelor's degree of Pharmacy from Gujarat University and a Master of Pharmacy (M.Pharm in Ayurved) from Gujarat Ayurved University, Jamnagar. With a strong passion for Ayurvedic formulations, he brings over 16 years of experience in the herbal and Ayurvedic industries, specializing in quality control, research & development, and technical management. he leads the Company's R&D initiatives, product innovation, and technical strategy, driving growth through science-based solutions and sustainable practices.



PARASKUMAR VINUBHAI PARMAR
Promoter and Director

With a Bachelor's degree of Pharmacy from Gujarat University and a Master's degree in International Business from the University of Greenwich, London. A Registered Pharmacist with the State Pharmacy Council, Gujarat, he brings extensive expertise in financial management, international business, and strategic growth. he plays a vital role in driving financial strategy, ensuring compliance, and supporting the Company's sustainable expansion in the CDMO manufacturing sector.



HARSHAD NANUBHAI RATHOD
Promoter and Director

With a Bachelor's degree of Pharmacy from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal. With over 15 years of experience in the Healthcare sector, he has expertise in business development, strategic planning, and financial oversight. As a Director, he contributes to guiding business expansion, fostering key relationships, and supporting the Company's long-term growth and innovation.



VIVEK ASHOKKUMAR PATEL
Promoter and Director

With a Bachelor's degree of Pharmacy from LJIP, Ahmedabad, and an MBA in Pharmaceutical Management from DY Patil Institute, he brings 14 years of experience in the healthcare sector. He has developed strong expertise in procurement, production, quality control, supply chain management, and overall business operations. His broad-based experience and leadership have been instrumental in guiding the Company's strategic direction and driving operational growth, thereby strengthening its position in the healthcare sector.



HARDIK MUKUNDBHAI PRAJAPATI
Promoter and Director

With Bachelor's of Pharmacy from LJIP, Ahmedabad, & a Master of Pharmacy from Gujarat Technological University (GTU). With over 15 years of experience in Healthcare sectors, he began his career with Lincoln Pharmaceuticals Ltd., gaining valuable expertise in manufacturing operations. His M.Pharm research on the formulation and development of controlled porosity osmotic pump tablets was published in "Inventi Journals" in June 2012. As a Director of the Company, he contributes his technical expertise & industry knowledge to support the Company's strategic growth and governance.

BOARDS' REPORT

Dear Members,

Your directors have pleasure in presenting **4th Annual Report** together with audited financial statement for the financial year ended on 31st March, 2025.

1. DISCLOSURE OF FINANCIAL SUMMARY OR HIGHLIGHTS

The Company's financial performance, for the year ended 31st March, 2025 is summarized below:

(Rs in lacs)

Particulars	For the Financial year ended on	
	31.03.2025	31.03.2024
Revenue from Operation	1,600.18	500.52
Other Income	0.62	12.78
Total Revenue	1,600.80	513.30
Total Expenditure	1,285.47	442.02
Profit (Loss) before Tax	315.33	71.28
Tax Expenses	65.24	(1.05)
Profit (Loss) after Tax	250.09	72.33
Earnings Per Share (Basic & Diluted)	68.83	20.09

2. BOARD MEETINGS

During the year under review, the Board of Directors met 11 times as under:

Sr. No.	Date of Meeting	Total Number of directors as on the date of meeting	Attendance	
			Number of directors attended	% of attendance
1.	29/06/2024	5	5	100
2.	24/09/2024	5	5	100
3.	20/11/2024	5	5	100
4.	28/11/2024	5	5	100
5.	21/12/2024	5	5	100
6.	17/02/2025	5	5	100
7.	01/03/2025	6	6	100
8.	02/03/2025	6	6	100
9.	20/03/2025	6	6	100
10.	21/03/2025	6	6	100
11.	28/03/2025	6	6	100

The intervening gap between two consecutive Board meetings is within the time prescribed under Companies Act, 2013 as well in compliance of Secretarial Standard – 1.

3. COMMITTEE MEETINGS

The board has not constituted any sub-committee as same is not required under applicable provisions of Companies Act, 2013.

4. DIRECTOR'S RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors state that:

1. in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
2. the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
3. the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
4. the Directors had prepared the annual accounts on a going concern basis; and
5. the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

5. FRAUDS REPORTED BY AUDITORS

The Auditor has not reported any frauds which are required to be reported by the auditors under sub-section (12) of section 143 of the Companies Act, 2013.

6. DECLARATION OF INDEPENDENCE

A statement on declaration given by independent Directors under sub-section (6) of section 149 of the Companies Act, 2013 is not applicable.

7. DISCLOSURE FOR COMPANIES COVERED UNDER SECTION 178(1) ON DIRECTORS' APPOINTMENT AND REMUNERATION INCLUDING OTHER MATTERS PROVIDED UNDER SECTION 178(3):

The Company was not required to constitute a Nomination and Remuneration Committee under Section 178 (1) of the Companies Act, 2013 and Rule (6) of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178 (5) of the Companies Act, 2013. Hence, disclosure under 178 is not applicable.

8. DETAILS OF LOAN, GUARANTEE, INVESTMENT OR SECURITY IS GIVEN BY THE COMPANY AS PER SECTION 186

During the year under review, the Company has not granted any Loans, or provided any guarantee or made investments as covered under Section 186 of the Companies Act, 2013 and complied with the applicable provisions.

9. STATE OF COMPANY'S AFFAIRS (Amount In Rupees)

The Directors of your Company are pleased to report that during the year under review, the Company has carried out business operations and achieved a total revenue of ₹ 16,00,18,000/- for the year ended, as against ₹ 5,00,52,000/- in the previous financial year. The Company has earned a net profit of ₹ 2,50,09,000/- during the year, as compared to a net profit of ₹ 72,33,000/- in the previous year.

To cater long-term working capital and capital expenditure outlay and expansion of business of the Company, the company is planning to raise further capital in the form of IPO. Your company has taken various steps towards IPO process including conversion of Private Limited into public company, appointment of Woman and Independent Directors, appointment of Key Managerial Personnel etc. in compliance of the provisions of the Act and various securities laws.

Your directors are hopeful for the brighter future of the company in the years to come.

10. TRANSFER OF AMOUNT TO RESERVES

During the year under report, the company has not transferred any amount to the reserves.

11. DECLARATION OF DIVIDEND

The board of directors of your company does not recommend any dividend for the year and has not declared interim dividend during year under review.

12. DETAILS OF MATERIAL CHANGES AND COMMITMENT OCCURRED DURING THE PERIOD BETWEEN THE END OF FY AND THE DATE OF REPORT, AFFECTING FINANCIAL POSITION OF COMPANY

After closure of Financial, Company converted from Private Limited Company to Limited Company by passing a Special resolution dated 12th April, 2025 and Registrar of Companies, CRC has issued Certificate of Incorporation Consequent upon conversion to public company on 02/05/2025. Except this, there is no material changes and commitments occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report affecting the financial position of the.

13. RISK MANAGEMENT POLICY

The Company has developed and implemented a risk management policy which identifies major risks which may threaten the existence of the Company. The same has also been adopted by your Board and is also subject to its review from time to time. Risk mitigation process and measures have been also formulated and clearly spelled out in the said policy.

14. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

A. Conservation of energy

- a. the steps taken or impact on conservation of energy - Nil
- b. the steps taken by the company for utilizing alternate sources of energy - Nil
- c. the capital investment on energy conservation equipments - Nil

B. Technology absorption

- a. the efforts made towards technology absorption - Nil
- b. the benefits derived like product improvement, cost reduction, product development or import substitution in case of imported technology - Nil
- c. the expenditure incurred on Research and Development - Nil

C. Foreign Exchange earnings and Outgo

a. Foreign Exchange Earnings – Rs. 54,02,000

b. Foreign Exchange Outgo – Nil

15. STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR

The Company is not required to appoint Independent Directors. Hence disclosure under Rule 8 (5) (iia) is not applicable.

16. INTERNAL FINANCIAL CONTROL

The Company has in place adequate internal financial controls with reference to financial statements. During the year, such controls were tested and no reportable material weakness in the design or operation was observed.

17. COST RECORDS

Maintenance of cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013, is not required by the Company.

18. APPLICATION OR PROCEEDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

No any application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 during the year.

19. ONE TIME SETTLEMENT

the details of difference between amount of the valuation done at the time of one-time settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof is not applicable as no such instance arise.

20. DISCLOSURE OF CHANGE IN NATURE OF BUSINESS

During the year under review, there were no changes in the nature of the business of the company during year under review.

21. DETAILS OF DIRECTORS OR KEY MANAGERIAL PERSONNEL WHO WERE APPOINTED OR HAVE RESIGNED DURING YEAR

Mr. Paraskumar Vinubhai Parmar (DIN: 10952040) was appointed as an additional director of the Company w.e.f. 17.02.2025. The Company has received a notice in writing from a member under Section 160 of the Companies Act, 2013 signifying his intention to propose, Mr. Paraskumar Vinubhai Parmar (DIN: 10952040) as a candidate for the office of the director of the Company. Board recommends his appointment as a director at ensuing Annual general Meeting.

Board recommends the following appointment of director and changes in designation/terms of director at ensuing Annual general Meeting.

1. Appointment of Mr. Paraskumar Vinubhai Parmar (DIN: 10952040) as Executive Director of the company.
2. Appointment of Mr. Mayur Popatlal Sojitra (DIN: 09108404) as Managing Director of the company.
3. Appointment of Mr. Ankurkumar Shantilal Patel (DIN: 09130391) as Whole-time Director of the company.
4. Appointment of Mr. Arun Das (DIN: 09657537) as an independent Director of the company.
5. Appointment of Mr. Mahipal Singh Chouhan (DIN: 08977710) as an independent Director of the company.
6. Appointment of Ms. Shruti Gupta (DIN: 10310259) as an independent Director of the company.

The composition of the Board of Directors as on 31st March, 2025 is as under:

Sr. No.	Name of Director	DIN	Designation
1.	Vivek Ashok Kumar Patel	09130357	Director
2.	Ankurkumar Shantilal Patel	09130391	Director
3.	Harshad Nanubhai Rathod	09108392	Director
4.	Hardik Mukundbhai Prajapati	09108403	Director
5.	Mayur Popatlal Sojitra	09108404	Director
6.	Paraskumar Vinubhai Parmar	10952040	Additional Director

Pursuant to the provisions of Section 152 of the Companies Act, 2013, Mr. Harshad Nanubhai Rathod (DIN: 09108392), Director, is liable to retire by rotation at the ensuing Annual General Meeting (AGM) of the Company and, being eligible, has offered himself for re-appointment. The Board of Directors recommends his re-appointment for the approval of the shareholders at the AGM.

Further Provisions related to Appointment of Key Managerial Personnel u/s 203 of the Companies Act, 2013 is not applicable to the company.

Further, After closure of financial year:

1. CS Payal Hareshbhai Kotadiya [ACS A77545] has been appointed as Company Secretary and Compliance Officer of the company with effect from 06/09/2025.
2. Mr. Paraskumar Vinubhai Parmar (DIN: 10952040) has been appointed as Chief Financial officer of the Company w.e.f. 11/09/2025.

22. DEPOSITS ACCEPTED DURING YEAR

The Company has not invited/ accepted any deposits from the public during the year ended March 31, 2025. There were no unclaimed or unpaid deposits or interest thereon as on March 31, 2025. The company has availed unsecured loans from its directors and director's relatives.

23. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNALS IMPACTING GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE

During the year under review, no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

24. PERFORMANCE EVALUATION

The statement indicating the manner in which formal annual evaluation has been made by the Board of its own performance and that of its committees and individual directors is not applicable to the Company.

25. A STATEMENT THAT THE COMPANY HAS COMPLIED WITH PROVISIONS RELATING TO THE CONSTITUTION OF INTERNAL COMPLAINTS COMMITTEE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013.

The Company maintains a zero-tolerance policy towards sexual harassment at the workplace. The Company has adopted a policy on prevention, prohibition, and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder, as amended from time to time.

The Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

(a) number of complaints of sexual harassment received in the year; - Nil

(b) number of complaints disposed off during the year; - Nil

(c) number of cases pending for more than ninety days - Nil

26. A STATEMENT WITH RESPECT TO THE COMPLIANCE OF THE PROVISIONS RELATING TO THE MATERNITY BENEFIT ACT, 1961

The Company has complied with provisions of Maternity Benefit Act.

27. SHARE CAPITAL

During the year under review, Following changes in capital Structure of the Company:

1. The Authorized capital of the Company is increased from Rs. 36,00,000 to Rs. 6,00,00,000 by passing an ordinary resolution dated 01/03/2025.
2. The paid-up capital increased from Rs.36,00,000 to Rs.45,00,000 by issue of 90000 Equity shares are allotted on right basis by passing a Board resolution dated 20/03/2025.
3. The paid-up capital increased from Rs.45,00,000 to Rs.48,70,000 by issue of 37000 Equity shares are allotted on right basis by passing a Board resolution dated 28/03/2025.

Further, the Company has not issued shares with differential voting rights nor granted stock options nor sweat equity. The Company has also not purchased its own shares by employees or by trustees for the benefit of the Company.

After closure of financial year under review, Following changes in capital Structure of the Company:

1. The paid-up capital increased from Rs.48,70,000 to Rs.53,20,000 by issue of 45000 Equity shares are allotted on right basis by passing a Board resolution dated 06/09/2025.
2. The paid up capital increased from Rs.53,20,000 to Rs.5,32,00,000 by issue of 4788000 Equity shares are allotted as Bonus shares by passing a Board resolution dated 10/09/2025.

Further, Board proposed to increase authorized capital of the company from Rs. 6,00,00,000 to Rs. 8,00,00,000 at ensuing Annual General Meeting.

28. TRANSFER OF SHARES

During the year under review, transfer of shares as per details given below:

Date of Transfer	Name of the Transferor with Folio no. (Seller)	Name of the Transferee with Folio No. (Buyer)	No. of Shares
28/11/2024	Hardik Mukundbhai Prajapati Folio No. 01	Paraskumar V. Parmar Folio No. 06	18000
28/11/2024	Hardik Mukundbhai Prajapati Folio No. 01	Vaishaki Hardik Prajapati Folio No. 07	10000
28/11/2024	Harshad Nanubhai Rathod Folio No. 02	Paraskumar V. Parmar Folio No. 06	18000
28/11/2024	Harshad Nanubhai Rathod Folio No. 02	Pooja Harshad Rathod Folio No. 08	10000
28/11/2024	Mayurbhai Popatlal Sojitra Folio No. 03	Paraskumar V. Parmar Folio No. 06	18000
28/11/2024	Mayurbhai Popatlal Sojitra Folio No. 03	Shweta Sojitra Folio No. 09	10000
28/11/2024	Vivek Ashok Kumar Patel Folio No. 05	Paraskumar V. Parmar Folio No. 06	18000
28/11/2024	Vivek Ashok Kumar Patel Folio No. 05	Paraskumar V. Parmar Folio No. 06	10000

29. ANNUAL RETURN

Pursuant to Section 134(3)(a) of the Act, the copy of draft annual return in form MGT-7 for financial period 2024-25 prepared in accordance with Section 92(3) of the Act is available on the website of the Company at <https://www.accretionnutraveda.com/>.

30. SUBSIDIARIES, JOINT VENTURE OR ASSOCIATE COMPANIES

The company does not have any subsidiaries, joint venture or associate companies. Therefore, there is no requirement to prepare consolidated financial statement for the Financial Year under review.

31. AUDITORS AND AUDITORS' REPORT

M/s V S S B & ASSOCIATES [ICAI Firm Registration No.: 121356W], Chartered Accountants, were appointed as Statutory Auditors of the Company, to fill casual vacancy arised due to resignation of K M V & Co. [ICAI Firm Registration No.: 139787W], at Extra-ordinary general meeting of the company held on 18/07/2025 to hold office till the conclusion of next annual general Meeting. Board recommended their re-appointment as statutory auditor for 5 Consecutive financial year commencing from the conclusion of the 4th Annual General Meeting of the company till the conclusion of 9th Annual General Meeting of the company to be held in the year 2030.

The Notes on financial statement referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation or adverse remark.

32. CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All Related Party Transactions entered during the financial year 2024-25 were in compliance to the provisions of law and were entered with the approval of Board and Shareholders, wherever applicable.

All related party transactions executed during the financial year were on arm's length basis, ordinary course of business and in accordance with the provisions of the Act and the rules made thereunder.

During the year, your Company has not entered into any transactions with related parties which could be considered material in terms of Section 188 of the Companies Act, 2013. Accordingly, the disclosure in Form AOC-2 pursuant to compliance of Section 134(3)(h) of the Companies Act, 2013 and Rule 8(2) of the Companies (Accounts) Rules, 2014 is not applicable to the Company for 2024-25 and hence does not form part of this report.

Your Company did not enter into any related party transactions during the year under review, which could be prejudicial to the interest of minority shareholders.

33. SECRETARIAL STANDARDS

During the year under review, the company has complied with the applicable secretarial standards.

34. SECRETARIAL AUDIT

During the year under review, secretarial audit as per section 204(3) of the Companies Act, 2013 is not applicable to the Company.

35. THE FOLLOING CLAUSES OF SECTION 134 ARE NOT APPLICABLE TO THE COMPANY:

Details of employees drawing remuneration of more than Rs. 8.5 Lakhs per month or Rs. 1.02 Crores per annum as prescribed under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016.

36. ACKNOWLEDGEMENT:

Your directors acknowledge with thanks the support and co-operation extended by the Investors, Bankers, Business Associates and employees at all levels for their valuable patronage.

For and on Behalf of the Board of Directors of

ACCRETION NUTRAVEDA LIMITED

Harshad Nanubhai Rathod

Director

DIN: 09108392

Mayur Popatlal Sojitra

Director

DIN: 09108404

Place: Ahmedabad

Date: 11/09/2025

Balance Sheet as at 31 March 2025

(Rs in lacs)

Particulars	Note	31 March 2025	31 March 2024
I. EQUITY AND LIABILITIES			
(1) Shareholders' Funds			
(a) Share Capital	3	48.70	36.00
(b) Reserves and Surplus	4	456.49	54.00
(c) Money Received against Share Warrants		-	-
Total		505.19	90.00
(2) Share application money pending allotment			
		-	-
(3) Non-current liabilities			
(a) Long-term Borrowings	5	246.05	67.71
(b) Deferred Tax Liabilities (Net)		-	-
(c) Other Long term Liabilities		-	-
(d) Long-term Provisions		-	-
Total		246.05	67.71
(4) Current liabilities			
(a) Short-term Borrowings	6	139.82	149.65
(b) Trade Payables	7		
- Due to Micro and Small Enterprises		24.43	47.57
- Due to Others		64.71	41.45
(c) Other Current Liabilities	8	17.54	37.80
(d) Short-term Provisions	9	56.17	0.30
Total		302.67	276.77
Total Equity and Liabilities		1,053.91	434.48
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	10	183.21	118.15
(ii) Intangible Assets		-	-
(iii) Capital Work-in-progress		-	-
(iv) Intangible Assets under Development		-	-
(b) Non-current Investments		-	-
(c) Deferred Tax Assets (net)	11	0.65	0.80
(d) Long-term Loans and Advances		-	-
(e) Other Non-current Assets		-	-
Total		183.86	118.95
(2) Current assets			
(a) Current investments		-	-
(b) Inventories	12	459.04	237.96
(c) Trade Receivables	13	326.65	24.95
(d) Cash and cash equivalents	14	1.54	11.90
(e) Short-term Loans and Advances	15	82.82	40.72
(f) Other Current Assets		-	-
Total		870.05	315.53
Total Assets		1,053.91	434.47

Significant Accounting Policy

2

See accompanying notes to the financial statements

As per our report of even date

For M/s V S S B & Associates

Chartered Accountants

Firm's Registration No. 0121356W

Vishves A. Shah

Partner

Membership No. 109944U

DIN: 25109944BMGPOH9829

Place: Ahmedabad

Date: 23 July 2025

For and on behalf of the Board of

ACCRETION NUTRAVEDA LIMITED

Harshad Rathod

Director

DIN: 09108392

Vivek Patel

Director

DIN: 09130357

Place: Ahmedabad

Date: 23 July 2025

Statement of Profit and loss for the year ended 31 March 2025

(Rs in lacs)

Particulars	Note	31 March 2025	31 March 2024
Revenue from Operations	16	1,600.18	500.52
Other Income	17	0.62	12.78
Total Income		1,600.80	513.30
Expenses			
Cost of Material Consumed	18	1,152.15	416.41
Purchases of Stock in Trade		-	-
Change in Inventories of work in progress and finished goods	19	(95.38)	(129.83)
Employee Benefit Expenses	20	45.65	26.29
Finance Costs	21	35.49	23.94
Depreciation and Amortization Expenses	22	22.14	24.12
Other Expenses	23	125.42	81.09
Total expenses		1,285.47	442.02
Profit/(Loss) before Exceptional and Extraordinary Item and Tax		315.33	71.28
Exceptional Item		-	-
Profit/(Loss) before Extraordinary Item and Tax		315.33	71.28
Prior Period Item		-	-
Extraordinary Item		-	-
Profit/(Loss) before Tax		315.33	71.28
Tax Expenses	24		
- Current Tax		53.72	-
- Deferred Tax		0.15	(1.05)
- MAT Credit Entitlement		-	-
- Prior Period Taxes		-	-
- Excess/Short Provision Written back/off		11.37	-
Profit/(Loss) for the Period from Continuing Operations		250.09	72.33
Profit/(loss) from Discontinuing Operation (before tax)		-	-
Tax Expenses of Discontinuing Operation		-	-
Profit/(loss) from Discontinuing Operation (after tax)		-	-
Profit/(Loss) for the period		250.09	72.33
Earnings Per Share (Face Value per Share Rs.10 each)			
-Basic (In Rs)	25	68.83	20.09
-Diluted (In Rs)	25	68.83	20.09
Significant Accounting Policy	2		

See accompanying notes to the financial statements

As per our report of even date

For M/s V S S B & Associates

Chartered Accountants

Firm's Registration No. 0121356W

Vishves A. Shah

Partner

Membership No. 109944

UDIN: 25109944BMGPOH9829

Place: Ahmedabad

Date: 23 July 2025

For and on behalf of the Board of

ACCRETION NUTRAVEDA LIMITED

Harshad Rathod

Director

DIN: 09108392

Vivek Patel

Director

DIN: 09130357

Place: Ahmedabad

Date: 23 July 2025

Cash Flow Statement for the year ended 31 March 2025

(Rs in lacs)

Particulars	Note	31 March 2025	31 March 2024
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		315.33	71.28
Depreciation and Amortisation Expense		22.14	24.12
Interest Income		(0.15)	(6.91)
Finance Costs		27.84	22.13
Operating Profit before working capital changes		365.16	110.62
Adjustment for:			
Inventories		(221.07)	(108.45)
Trade Receivables		(301.70)	39.57
Loans and Advances		(42.10)	(1.75)
Trade Payables		0.12	(76.12)
Other Current Liabilities		(20.26)	37.80
Short-term Provisions		55.87	0.12
Cash (Used in)/Generated from Operations		(163.98)	1.80
Tax paid(Net)		65.09	-
Net Cash (Used in)/Generated from Operating Activities		(229.07)	1.80
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Property, Plant and Equipment		(87.20)	(3.32)
Dividend received		0.15	6.91
Net Cash (Used in)/Generated from Investing Activities		(87.05)	3.59
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of Share Capital		165.10	-
Proceeds from Long Term Borrowings		178.34	-
Proceeds from Short Term Borrowings		(9.83)	20.03
Interest Paid		(27.84)	(22.13)
Net Cash (Used in)/Generated from Financing Activities		305.77	(2.10)
Net Increase/(Decrease) in Cash and Cash Equivalents		(10.36)	3.29
Opening Balance of Cash and Cash Equivalents		11.90	8.61
Exchange difference of Foreign Currency Cash and Cash equivalents		-	-
Closing Balance of Cash and Cash Equivalents	14	1.54	11.90
Components of cash and cash equivalents		31 March 2025	31 March 2024
Cash on hand		1.54	11.90
Balances with banks in current accounts		-	-
Cash and cash equivalents as per Cash Flow Statement		1.54	11.90

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting

See accompanying notes to the financial statements

As per our report of even date

For M/s V S S B & Associates

Chartered Accountants

Firm's Registration No. 0121356W

Vishves A. Shah

Partner - Membership No. 109944

UDIN: 25109944BMGPOH9829

Place: Ahmedabad

Date: 23 July 2025

For and on behalf of the Board of

ACCRETION NUTRAVEDA LIMITED

Harshad Rathod

Director

DIN: 09108392

Vivek Patel

Director

DIN: 09130357

Place: Ahmedabad

Date: 23 July 2025

INDEPENDENT AUDITOR'S REPORT

**To,
The Members of,
ACCRETION NUTRAVEDA LIMITED
Report on the Audit of the Standalone Financial Statements**

Opinion

We have audited the accompanying Standalone financial statements of **Accretion Nutraveda Limited** ("the Company"), which comprise the balance sheet as at 31st March 2025, and the statement of profit and loss and statement of cash flows and notes to the financial statement, for the year ended 31st March 2025, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements gives the information required by the Companies Act, 2013 ("the ACT") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2025, and its **Profit**, its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on Standalone Financial Statement.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our report.

Sr. No.	Key Audit Matter	How our audit addressed the key audit matter
01	<p>Revenue recognition:</p> <p>Refer note 19 to the standalone financial statements.</p> <p>The Revenues of the Company consists primarily of sale of products and is recognized when control of products being sold is transferred to customer and there is no unfulfilled obligation.</p> <p>Revenue is measured at fair value of the consideration received or receivable and is accounted for net of trade discounts.</p> <p>Considering the materiality of amounts involved, the same has been considered as a key audit matter</p>	<p>Our key procedures included, but were not limited to, the following:</p> <p>a) Assessed the appropriateness of the Company's revenue recognition accounting policies, including those relating to trade discounts by comparing with the applicable accounting standards;</p> <p>b) Tested the design and operating effectiveness of the general IT control environment and the manual controls for recognition of revenue, calculation of discounts;</p> <p>c) Performed test of details:</p> <ul style="list-style-type: none"> - Tested, on a sample basis, sales transactions to the underlying supporting documentation which includes goods dispatch notes and shipping documents; - Reviewed, on a sample basis, sales agreements and the underlying contractual terms related to delivery of goods, Company's revenue recognition policies with reference to the requirements of the applicable accounting standards; - Obtained supporting documentation for a sample of credit notes issued after the year end to determine whether the transaction was recognized in the correct accounting period; and <p>Assessed the appropriateness of the Company's description of the accounting policy, disclosures related to discounts, and incentives and whether these are adequately presented in the standalone financial statements.</p>

Information other than the financial statements and Auditor's Report Thereon

The Company's Board of Directors are responsible for the other information. The other information comprises the information included in annual report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those charged with governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, cash flows in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial statements.

As part of an audit in accordance with Standards on Auditing, specified under section 143(10) of the Act we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Standalone Financial statement in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.

- However, future events or conditions may cause the Company to cease to continue as a going concern, and
- Evaluate the overall presentation, structure and content of the Standalone Financial statements, including the disclosures, and whether the Standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced.

We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The standalone financial statements dealt with by this report are in agreement with the books of account;
- (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of section 164(2) of the Act;
- (f) The modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph (b) above on reporting under section 143(3)(b) and in sub-clause (2)(h)(F) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014;
- (g) With respect to the adequacy of the internal financial controls with reference to Standalone Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to the Standalone Financial Statement.
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

- A. The Company does not have any pending litigations which would impact its financial position
- B. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2025;
- C. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended 31 March 2025;
- D. (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (ii) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (iii) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) of the Companies (Audit and Auditors) Rules, 2014, as provided under (a) and (b) above, contain any material misstatement.
- E. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.
- F. Based on our examination which included test checks, we concluded that company has used accounting softwares for maintaining its books of account which have a feature of recording audit trail (edit log) facility but the same has not been operated throughout the year for all relevant transactions recorded in the respective softwares:
- i. In respect of the Company, the feature of recording audit trail (edit log) facility was not enabled at the database layer to log any direct data changes for all the accounting softwares used for maintaining the books of account.
- ii. In respect of the Company, in the absence of coverage of audit trail (edit log) with respect to database level in the independent auditor's report in relation to controls at the service organisation for accounting software used for preparation of financial statements, which is operated by third-party software service provider, we are unable to comment whether the audit trail feature of the database level of the said software was enabled and operated throughout the year for all relevant transactions recorded in the software. Further, where audit trail (edit log) facility was enabled and operated, we did not come across any instance of the audit trail feature being tampered with.

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

3. As required by section 197(16) of the Act based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.

Date: 23/07/2025

Place: Ahmedabad

For, V S S B & Associates
Chartered Accountants
Firm No. 0121356W
(Vishves A. Shah) - Partner
M. No. 109944
UDIN:25109944BMGPOH9829

Annexure A” to Independent Audit Report

(Referred to in paragraph 1(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls with reference to Standalone Financial Statement under clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the Internal Financial Controls with reference to Standalone Financial Statements of **Accretion Nutraveda Private Limited** (“the Company”) as of 31st March, 2025 in conjunction with our audit of the Standalone Financial Statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to Standalone Financial Statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls with reference to Standalone Financial Statements of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under - section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to Standalone Financial Statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Standalone Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to Standalone Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Standalone Financial Statements included obtaining an understanding of internal financial controls with reference to Standalone Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls with reference to Standalone Financial Statements.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control with reference to Standalone Financial Statement is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls with reference to Standalone Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Standalone Financial Statements to future periods are subject to the risk that the internal financial control with reference to Standalone Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with reference to Standalone Financial Statements and such internal financial controls with reference to Standalone Financial Statements were operating effectively as at 31st March, 2025, based on the criteria for internal financial control with reference to Standalone Financial Statements established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Date: 23/07/2025

Place: Ahmedabad

For, V S S B & Associates

Chartered Accountants

Firm No. 0121356W

(Vishves A. Shah)

Partner

M. No. 109944

UDIN: 25109944BMGPOH9829

“ANNEXURE B” to the Independent Audit Report

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- (i.) In respect of the Company's Property, Plant and Equipment and Intangible Assets:
- (a) (i) According to the information and explanation given to us and the records produced to us for our verification, the Company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
 - (ii) According to the information and explanation given to us and the records produced to us for our verification, the Company has no intangible assets during the financial year. Hence this clause is not applicable.
 - (b) According to the information and explanation given to us and the records produced to us for our verification, the Company has a regular programme of physical verification of its Property, Plant and Equipments by which all Property, Plant and Equipments are verified by the management at least once in every three years. In accordance with this programme, certain Property, Plant and Equipment were verified during the year and the discrepancies noticed on verification were not material and have been appropriately dealt with in the books of accounts. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
 - (c) According to the information and explanation given to us and the records produced to us for our verification, the title deeds of all the immovable properties disclosed in the Standalone Financial Statements are held in the name of the Company.
 - (d) According to the information and explanation given to us and the records produced to us for our verification, the Company has not revalued its Property, Plant and Equipment (including ROU) or intangible assets or both during the year. Accordingly, clause 3(i)(d) of the Order is not applicable.
 - (e) According to the information and explanation given to us and the records produced to us for our verification, no proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) and rules made thereunder
- (ii) In respect of the Company's Inventories
- (a) The Inventory other than goods in transit, have been physically verified by the management during the year at reasonable intervals. In our opinion, the frequency of verification is reasonable and the coverage and procedure of such verification is appropriate. The discrepancies noticed on verification between the physical stocks and the book records were not 10% or more in aggregate and have been appropriately dealt with in the books of account.
 - (b) The company has not been sanctioned a working capital limit from banks or financial institutions on the basis of security of current assets at any point during the year. Accordingly, reporting under clause 3(ii)(b) of the Order is not applicable.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year other than loan to employees. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said Order are not applicable to the Company.

- (iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any loans, investments, guarantees and security on which provisions of Sections 185 and 186 of the Companies Act, 2013 are applicable. Therefore, the provisions of clause 3(iv) of the said Order are not applicable to the company.
- (v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or any amount deemed to be deposits from the public within the meaning of the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under. Accordingly, clause 3(v) of the Order is not applicable to the Company.
- (vi) The maintenance of cost records has not been specified by the Central Government under Section 148(1) of the Act, for the business activities carried out by the Company. Thus, reporting under clause (vi) of the Order is not applicable.
- (vii) According to the information and explanations given to us, in respect of statutory dues:
- (a) The Company has been regular in depositing disputed statutory dues, including Goods and Service Tax, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Cess and other material statutory dues in arrears as at 31st March, 2025 for a period of more than six months from the date they became payable.
- (b) There has been no statutory dues referred to in sub clause (a) in dispute. Hence, this clause is not applicable.
- (viii) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not surrendered or disclosed previously undisclosed transactions as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). Accordingly, clause 3(viii) of the Order is not applicable to the Company.
- (ix) In respect of loans and borrowings of the Company
- (a) Based upon the audit procedures performed, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender, although certain loans taken from related parties, which fell due during the year, were renewed/ extended prior to the due date and interest accrued and remaining unpaid has been added to loans outstanding at year end, as per terms of the agreement.
- (b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared willful defaulter by any bank, financial institution or any other lender.
- (c) According to the information and explanations given to us by the management, the Company has utilized the money obtained by way of term loan during the year for the purposes for which they were obtained.
- (d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the Standalone Financial Statements of the Company, we report that, prima facie, no funds raised on short term basis have been used by the Company for long-term purposes.
- (e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures as defined under the Act.
- (f) The Company does not have any subsidiaries, joint ventures or associate companies. Therefore, the question of raising loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies does not arise.
- (x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the financial year. Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.

- (xi) (a) During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practice in India, and according to the information and explanation given to us, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the Management there were no whistle-blower complaints received by the Company during the year and up to the date of this report. As represented to us by the Management there were no whistle-blower complaints received by the Company during the year and up to the date of this report.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- (xiii) In our opinion, the Company is in compliance with section 177 and 188 of the Companies Act where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements etc. as required by the applicable accounting standards.
- (xiv) In our opinion, the Company is not required to have an internal audit system u/s 138 of the Companies Act, 2013, Hence this clause is not applicable to the company.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions, within the meaning of Section 192 of the Act, with directors or persons connected with them.
- (xvi) a) In our opinion and according to the information and explanations given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3 (xvi) (a) of the Order is not applicable to the Company.
- b) According to the information and explanations given to us and based on our examination of the records of the Company the company has not conducted any Non-Banking Financial or Housing Finance activities. Accordingly, clause 3 (xvi) (b) of the Order is not applicable to the Company
- c) In our opinion and according to the information and explanations given to us, the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3 (xvi) (c) of the Order is not applicable to the Company.
- d) There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3 (xvi) (d) of the Order is not applicable to the Company.
- (xvii) Based on our examination of the records of the Company, the Company has not incurred any cash losses during the financial year covered by our audit and in the immediately preceding financial year.
- (xviii) There has been resignation of the statutory auditors during the year. We have duly obtained the No Objection certificate as on 26th May 2025 from the previous Auditor and also considered the observations of the outgoing auditors.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the Standalone Financial Statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx) There is no liability of the company under the provisions of section 135 of the Companies Act, relating to Corporate Social Responsibility. Therefore, the provisions of Clause (xx) of paragraph 3 of the order are not applicable to the Company.

(xxi) The reporting under clause (xxi) is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, Therefore, the provisions of Clause (xxi) of paragraph 3 of the order are not applicable to the Company.

Date: 23/07/2025

Place: Ahmedabad

For, V S S B & Associates

Chartered Accountants

Firm No. 0121356W

(Vishves A. Shah)

Partner

M. No. 109944

UDIN: 25109944BMGPOH9829

Notes forming part of the Financial Statements

1.

COMPANY INFORMATION

ACCRETION NUTRAVEDA LIMITED is a Public Limited company domiciled in India having CIN: U24290GJ2021PLC121216 having its registered office at 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta-Sanand, Ahmedabad, Ahmedabad, Gujarat, India, 382213. The Company is incorporated under the provisions of Companies Act, as applicable in India.

Accretion Nutraveda Limited is one of the most promising & rising groups in the Healthcare industry with a rich legacy of high-quality healthcare through Ayurveda, Nutraceuticals and Pharmaceutical products.

The company is mainly engaged in business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Nutraceutical Pharmaceuticals products and related products thereto.

Accretion Nutraveda Limited is companies, which includes a prominent Healthcare company with Accretion Pharmaceuticals a WHO-cGMP & GLP certified company that delivers effective pharmaceutical drug manufacturing.

2. SIGNIFICANT ACCOUNTING POLICIES

a Basis of Preparation

These standalone financial statements have been prepared to comply with the Generally Accepted Accounting Principles (Indian GAAP), including Accounting Standards notified under the relevant provisions of the Companies Act, 2013. The standalone financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies not specifically referred, are consistently applied from the past accounting periods.

b Use of Estimates

The preparation of standalone financial statements in conformity with the Generally Accepted Accounting Policies requires the management to make estimates and assumptions that affect the reported amount of assets, liabilities, revenues and expenses and disclosures of contingent assets and liabilities. The estimates and assumptions used in the accompanying standalone financial statements are based upon management's evaluation of the relevant facts and circumstances as on the date of the standalone financial statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying financial statements. Any differences of actual results to such estimates are recognized in the period in which the results are known/ materialized.

c Revenue Recognition

Revenue from contract with customer is recognised upon transfer of control of promised products or services to customers on complete satisfaction of performance obligations for an amount that reflects the consideration which the Company expects to receive in exchange for those products or services. Revenue is measured based on the transaction price, which is the consideration, adjusted for discounts and other incentives, if any, as per contracts with the customers. Revenue also excludes taxes or amounts collected from customers in its capacity as agent. The specific recognition criteria from various stream of revenue is described below:

Sale of goods: Revenue from the sale of products is recognized at the point in time when control is transferred to the customer. Revenue is measured based on the transaction price, which is the consideration, net of customer incentives, discounts, variable considerations, payments made to customers, other similar charges, as specified in the contract with the customer. Additionally, revenue excludes taxes collected from customers, which are subsequently remitted to governmental authorities.

Interest Income:

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

d Employee Benefits

Short Term Employee Benefits Employee benefits payable wholly within twelve months of rendering the services are classified as short-term employee benefits and recognized in the period in which the employee renders the related service. These are re-recognized at the undiscounted amount of the benefits expected to be paid in exchange for that service.

e Property, Plant and Equipment

a. Fixed Assets:-

Fixed Assets are value at cost less depreciation. The depreciation has been calculated as prescribed in Companies Act, 2013 on single shift and if the Asset is purchased during the year depreciation is provided on the days of utilisation in that year.

f Depreciation and amortization

In accordance with the provisions of the Companies Act, 2013, effective from April 1, 2014, the Company has revised the depreciation rates on tangible fixed assets based on the useful lives specified in Part 'C' of Schedule II of the Act.

Depreciation is calculated using the Written Down Value (WDV) Method over the estimated useful lives of the assets, as prescribed under Schedule II or as estimated by the management, wherever applicable.

Key Depreciation Policies:

Component Accounting:

Where the cost of a part of an asset is significant in relation to the total cost of the asset and the useful life of that part differs from the rest of the asset, such part is depreciated separately based on its own useful life.

Pro-rata Depreciation:

Depreciation is charged pro-rata for assets acquired or disposed of during the year – from the date the asset is available for use or until the date of disposal.

Measurement Basis:

Tangible fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Direct costs attributable to bringing the asset to its working condition for its intended use are capitalized.

Depreciation Rates:

Depreciation is provided on the Written Down Value method, at rates derived based on the useful lives specified in Schedule II to the Companies Act, 2013 or as estimated by the management in cases where the useful life differs from Schedule II.

Type of Assets**Useful Life**

Buildings - 9.50%	30 Years
Plant and Equipment - 18.10%	15 Years
Furniture and Fixtures - 25.89%	10 Years
Office equipment - 45%	5 Years
Processing Unit - 63.16%	3 Years

g Impairment of assets

At each balance sheet date, the management reviews the carrying amounts of its assets included in each cash generating unit to determine whether there is any indication that those assets were impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of impairment. Recoverable amount is the higher of an asset's net selling price and value in use. In assessing value in use, the estimated future cash flows expected from the continuing use of the asset and from its disposal are discounted to their present value using a pre-tax discount rate that reflects the current market assessments of time value of money and the risks specific to the asset. Reversal of impairment loss is recognised as income in the statement of profit and loss.

h Inventories

Raw materials are carried at the lower of cost and net realisable value. Cost is determined on a FIFO (First In First Out) basis. Purchased goods-in-transit are carried at cost. Work-in-progress is carried at the lower of cost and net realisable value. Stores and spare parts are carried at lower of cost and net realisable value. Finished goods produced or purchased by the Company are carried at lower of cost and net realisable value. Cost includes direct material and labour cost and a proportion of manufacturing overheads.

The valuation for inventories is as follows:

		(Rs in lacs)	
Classification	Valuation Policy	31 March 2025	31 March 2024
Finished Goods	At lower of cost or net realizable value.	77.56	27.85
Raw Material	At lower of cost or net realizable value.	233.84	108.13
WIP	At Cost	-	-
Consumables	At Cost	-	-

i Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short term balances (with an original maturity of three months or less from the date of acquisition) and highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdraft and are considered part of the Company's cash management system.

Cash Flow Statement (AS - 3)

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a noncash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

k Foreign currency transactions

Income and expense in foreign currencies are converted at exchange rates prevailing on the date of the transaction. Foreign currency monetary assets and liabilities other than net investments in non-integral foreign operations are translated at the exchange rate prevailing on the balance sheet date and exchange gains and losses are recognised in the statement of profit and loss. Exchange difference arising on a monetary item that, in substance, forms part of an enterprise's net investments in a non-integral foreign operation are accumulated in a foreign currency translation reserve.

l The Effect of changes in Foreign Exchange Rates:

An enterprise may carry on activities involving foreign exchange in two ways. It may have transactions in foreign currencies or it may have foreign operations.

Initial Recognition:

A foreign currency transaction is a transaction which is denominated in or requires settlement in a foreign currency, including transactions arising when an enterprise either:

(a) buys or sells goods or services whose price is denominated in a foreign currency; (b) borrows or lends funds when the amounts payable or receivable are denominated in a foreign currency; (c) becomes a party to an unperformed forward exchange contract; or (d) otherwise acquires or disposes of assets, or incurs or settles liabilities, denominated in a foreign currency. A foreign currency transaction should be recorded, on initial recognition in the reporting currency, by applying to the foreign currency amount, the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

At Balancesheet date

(a) foreign currency monetary items should be reported using the closing rate. However, in certain circumstances, the closing rate may not reflect with reasonable accuracy the amount in reporting currency that is likely to be realised from, or required to disburse, a foreign currency monetary item at the balance sheet date, e.g., where there are restrictions on remittances or where the closing rate is unrealistic and it is not possible to effect an exchange of currencies at that rate at the balance sheet date. In such circumstances, the relevant monetary item should be reported in the reporting currency at the amount which is likely to be realised from, or required to disburse, such item at the balance sheet date;

(b) non-monetary items which are carried in terms of historical cost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction; and

(c) non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rates that existed when the values were determined.

m Taxes on income

Current income tax expense comprises taxes on income from operations in India and in foreign jurisdictions. Income tax payable in India is determined in accordance with the provisions of the Income Tax Act, 1961. Tax expense relating to foreign operations is determined in accordance with tax laws applicable in countries where such operations are domiciled.

Deferred tax expense or benefit is recognised on timing differences being the difference between taxable income and accounting income that originate in one period and is likely to reverse in one or more subsequent periods. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date.

The Company offsets deferred tax assets and deferred tax liabilities if it has a legally enforceable right and these relate to taxes on income levied by the same governing taxation laws.

n Provisions and contingent liabilities

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits and compensated absences) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognised in the financial statements. A contingent asset is neither recognised nor disclosed in the financial statements.

o Current Assets, Loans, and Advances & Liabilities

In the Opinion of the Board, the value on realization of the current assets, loans and advances, if realized in the ordinary course of business, shall not be less than the amount, which is stated, in the current year Balance sheet. The provision for all known liabilities is reasonable and not in excess of the amount considered reasonably necessary.

p Earnings Per Shares

Basic earning per share is computed by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Diluted earning per share is computed by taking into account the weighted average number of equity shares outstanding during the period and the weighted average number of equity shares which would be issued on conversion of all dilutive potential equity shares into equity shares.

p Contributed Equity

Equity shares are classified as equityBasic earnings per share is calculated by dividing

- the profit attributable to the owners group
- by the weighted average number of equity shares outstanding during the year.

r Other Note

1. As per the Ministry of Corporate Affairs (MCA) notification, proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014, from the financial year commencing April 1, 2023, every company which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled. The interpretation and guidance on what level edit log and audit trail needs to be maintained evolved during the year and continues to evolve.

In the company, the accounting software has a feature of audit trail, but it was disable at an application level for maintenance of books of accounts and relevant transactions. However, the global standard ERP used by the Company has not been enabled with the feature of audit trail log at the database layer to log direct transactional changes, due to present design of ERP. This is being taken up with the vendor. In the meanwhile, the Company continues to ensure that direct write access to the database is granted only via an approved change management process.

3 NOTES FORMING PART OF ACCOUNTS

1. Balance of cash on hand at the end is accepted as certified by the management of the company.
2. The figures of the previous year are regrouped as and where required from the report of the previous auditor.
3. Balance of Trade Receivable, Trade Payable, Loans & advances are subject to confirmation of the parties taken from the Management of Company.
4. As certified by the company that it was received written representation from all the directors, that companies in which they are directors had not defaulted in terms of section 164(2) of the companies Act, 2013, and the representation from directors taken in Board that Director is disqualified from being appointed as Director of the company.

As per our report of even date

For M/s V S S B & Associates

Chartered Accountants

Firm's Registration No. 0121356W

For and on behalf of the Board of

ACCRETION NUTRAVEDA LIMITED

Vishves A. Shah

Partner

Membership No. 109944

UDIN: 25109944BMGPOH9829

Place: Ahmedabad

Date: 23 July 2025

Harshad Rathod

Director

DIN: 09108392

Vivek Patel

Director

DIN: 09130357

Place: Ahmedabad

Date: 23 July 2025

Notes forming part of the Financial Statements

3 Share Capital

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Authorised Share Capital		
Equity Shares, of Rs. 10 each, 6000000 (Previous Year -360000) Equity Shares	600.00	36.00
Issued, Subscribed and Fully Paid up Share Capital		
Equity Shares, of Rs. 10 each, 487000 (Previous Year -360000) Equity Shares paid up	48.70	36.00
Total	48.70	36.00

*The Company has only one class of Equity Shares having a par value of Rs. 10/- per share. Each holder of Equity Share is entitled to one vote per share.

During the year, company has issued equity shares of 127000 (90000 & 37000) having face value of Rs. 10 and Security premium of Rs. 120, in form of right issue.

(i) Reconciliation of number of shares

Particulars	31 March 2025		31 March 2024	
	No. of shares	(Rs in lacs)	No. of shares	(Rs in lacs)
Equity Shares				
Opening Balance	360,000	36.00	360,000	36.00
Issued during the year	127,000	12.70	-	-
Deletion	-	-	-	-
Closing balance	487,000	48.70	360,000	36.00

(ii) Rights, preferences and restrictions attached to shares

Equity Shares: 1) The Company has only one class of Equity Shares having a par value of Rs. 10/- per share. Each holder of Equity Share is entitled to one vote per share. The Company has not declared any dividend.

2) In the event of liquidation of the Company, the holders of Equity shares will be entitled to receive remaining assets of the

Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of Equity shares held by the shareholders.

(iii) Details of Shares held by shareholders holding more than 5% of the aggregate shares in the company

Equity Shares	31 March 2025		31 March 2024	
	No. of shares	In %	No. of shares	In %
Name of Shareholder				
Hardik Mukundbhai Prajapati	63,050	12.95%	72,000	20.00%
Harshad Nanubhai Rathod	63,050	12.95%	72,000	20.00%
Mayur Popatlal Sojitra	63,050	12.95%	72,000	20.00%
Ankurkumar Shantilal Patel	97,400	20.00%	72,000	20.00%
Vivek Ashokkumar Patel	63,050	12.95%	72,000	20.00%
Paraskumar Vinubhai Parmar	97,400	20.00%	-	0.00%
Vaishaki Hardik Prajapati	10,000	2.05%	-	0.00%
Pooja Harshad Rathod	10,000	2.05%	-	0.00%
Shweta Sojitra	10,000	2.05%	-	0.00%
Ankita Vivek Patel	10,000	2.05%	-	0.00%

(iv) Shares held by Promoters at the end of the year 31 March 2025

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Harshad Nanubhai Rathod	Equity	63,050	12.95%	-7.05%
Hardik Mukundbhai Prajapati	Equity	63,050	12.95%	-7.05%
Mayur Popatlal Sojitra	Equity	63,050	12.95%	-7.05%
Vivek Ashokkumar Patel	Equity	63,050	12.95%	-7.05%
Ankurkumar Shantilal Patel	Equity	97,400	20.00%	0.00%
Paraskumar Vinubhai Parmar	Equity	97,400	20.00%	20.00%

Shares held by Promoters at the end of the year 31 March 2024

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Harshad Nanubhai Rathod	Equity	72,000	20.00%	0.00%
Hardik Mukundbhai Prajapati	Equity	72,000	20.00%	0.00%
Mayur Popatlal Sojitra	Equity	72,000	20.00%	0.00%
Vivek Ashokkumar Patel	Equity	72,000	20.00%	0.00%
Ankurkumar Shantilal Patel	Equity	72,000	20.00%	0.00%
Paraskumar Vinubhai Parmar	Equity	-	0.00%	0.00%

(v) Equity shares movement during 5 years preceding 31 March 2025

Particulars	Year 1	Year 2	Year 3	Year 4	Year 5
Equity Shares issued as Right Issue		210,000			127,000
Equity Shares issued as Bonus Issue					
Equity shares extinguished on buy-back					

The Company has issued 90,000 equity shares as a Right Issue having paripassurank with the existing equity shares of the company vide meeting held of Board of Directors dated 20/03/2025, at a premium of Rs. 120 and having a face value of Rs. 10.

The Company has issued 37,000 equity shares as a Right Issue having paripassurank with the existing equity shares of the company vide meeting held of Board of Directors dated 28/03/2025, at a premium of Rs. 120 and having a face value of Rs. 10.

4 Reserves and Surplus

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Securities Premium		
Opening Balance	-	-
Add: Issue of Shares	152.40	-
Closing Balance	152.40	-
Statement of Profit and loss		
Balance at the beginning of the year	54.00	(18.33)
Add: Profit/(loss) during the year	250.09	72.33
Balance at the end of the year	304.09	54.00
Total	456.49	54.00

Nature of Reserve and Surplus**Securities Premium**

During the Year, Company has issued equity shares of 127000 having face value of Rs. 10 and Security premium of Rs. 120.

5 Long term borrowings

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Secured Term loans from banks		
-Term Loan: Indian Bank	53.05	67.71
Unsecured Term loans from banks		
-Axis Bank Limited	33.00	-
-Deutsche Bank AG	50.00	-
-ICICI Bank Limited	75.00	-
-Standard Chartered Bank	35.00	-
Total	246.05	67.71

Charge is created against the Indian Bank - Term Loan on hypothecation of Plant and Machinery purchased from bank finance along with all other fixed assets of the company.

6 Short term borrowings

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Secured Loans repayable on demand from banks		
-Indian Bank	139.82	74.59
Unsecured Loans and advances from related parties		
-Unsecured Loans and advances from Director	-	75.06
Total	139.82	149.65

Charge is created against the Indian Bank - Cash Credit Loan on hypothecation of stocks, book debts, and all other current assets of the company.

7 Trade payables

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Due to Micro and Small Enterprises		
-Trade Payables	24.43	47.57
Due to others		
-Payable for Capital Goods	1.40	2.48
-Payable for Salary	3.41	6.40
-Trade Payables	59.90	32.57
Total	89.14	89.02

7.1 Trade Payable ageing schedule as at 31 March 2025

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	24.43				24.43
Others	64.67	0.04			64.71
Disputed dues- MSME					-
Disputed dues- Others					-
Sub total					89.15
MSME - Undue					
Others - Undue					
Total					89.15

7.2 Trade Payable ageing schedule as at 31 March 2024

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	47.57	-			47.57
Others	39.48	1.97			41.46
Disputed dues- MSME					-
Disputed dues- Others					-
Sub total					89.02
MSME - Undue					
Others - Undue					
Total					89.02

Trade payables balances are re-grouped or re-arranged for current year and previous year, according to its ledger nature.

8 Other current liabilities

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Advances from customers	17.54	37.80
Total	17.54	37.80

9 Short term provisions

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Provision for income tax	53.72	-
Provision For Audit Fees	1.00	-
RCM GST Payable	0.26	0.01
TDS Payable	1.19	0.29
Total	56.17	0.30

Notes forming part of the Financial Statements

10 Property, Plant and Equipment

(Rs in lacs)

Name of Assets	Gross Block		Depreciation and Amortization			Net Block			
	As on 01-Apr-24	Addition	Deduction	As on 31-Mar-25	As on 01-Apr-24	for the year	Deduction	As on 31-Mar-25	As on 31-Mar-24
(i) Property, Plant and Equipment									
Factory Building - 9.50%	20.46	12.12	-	32.58	4.14	2.22	-	6.37	16.32
Plant & Machinery - 18.10%	164.66	75.08	-	239.74	66.65	18.89	-	85.54	98.01
Furniture & Fixtures - 25.89%	4.62	-	-	4.62	1.02	0.93	-	1.95	3.61
Office Equipments computer data - 45%	0.83	-	-	0.83	0.63	0.09	-	0.72	0.20
Processing Unit - 63.16%	0.16	-	-	0.16	0.15	0.01	-	0.15	0.01
Total	190.73	87.20	-	277.93	72.59	22.14	-	94.73	118.15
Previous Year	187.42	3.32	-	190.73	48.47	24.12	-	72.59	138.95

Notes forming part of the Financial Statements

11 Deferred tax assets net

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Deferred tax assets net	0.65	0.80
Total	0.65	0.80

11.1 Significant Components of Deferred Tax

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Deferred Tax Asset		
Difference between book depreciation and tax depreciation	0.65	0.80
Gross Deferred Tax Asset (A)	0.65	0.80
Deferred Tax Liability		
Gross Deferred Tax Liability (B)	-	-
Net Deferred Tax Asset (A)-(B)	0.65	0.80

12 Inventories

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Raw materials	233.84	108.13
Work-in-progress	147.64	101.97
Finished goods	77.56	27.85
Total	459.04	237.96

13 Trade receivables

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Unsecured considered good	326.65	24.95
Total	326.65	24.95

13.1 Trade Receivables ageing schedule as at 31 March 2025

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	325.27	1.01	0.37			326.65
Undisputed Trade Receivables- considered doubtful						-
Disputed Trade Receivables considered good						-
Disputed Trade Receivables considered doubtful						-
Sub total						326.65
Undue - considered good						
Total						326.65

Notes forming part of the Financial Statements

13.2 Trade Receivables ageing schedule as at 31 March 2024

(Rs in lacs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	24.95					24.95
Undisputed Trade Receivables- considered doubtful						-
Disputed Trade Receivables considered good						-
Disputed Trade Receivables considered doubtful						-
Sub total						24.95
Undue - considered good						
Total						24.95

Trade receivables balances are re-grouped or re-arranged for current year and previous year, according to its ledger nature.

14 Cash and cash equivalents

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Cash on hand	1.54	11.90
Total	1.54	11.90

15 Short term loans and advances

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Loans and advances to employees	0.75	0.36
Advances to suppliers	10.00	4.17
Balances with Government Authorities		
- Advance Tax	30.00	-
- GST Receivable	25.73	29.64
- TDS & TCS Receivable	0.93	0.33
Others		
- Security Deposits	15.41	6.22
Total	82.82	40.72

16 Revenue from operations

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Sale of products		
- Domestic Sales	1,546.17	491.18
- Export Sales	54.01	9.34
Total	1,600.18	500.52

Notes forming part of the Financial Statements

17 Other Income

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Cash Discount Received	-	0.02
CGTMSE Subsidy Income	-	5.75
Discount Income	-	0.07
Duty Drawback	0.47	0.01
Interest on It Refund	-	0.02
Interest on Ugvcl Deposit	0.15	0.14
Intrest Subsidy Received	-	6.77
Total	0.62	12.78

18 Cost of Material Consumed

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Raw Material Consumed		
Opening stock	108.13	129.52
Purchases	1,277.86	395.02
Less: Closing stock	233.84	108.13
Total	1,152.15	416.41
Total	1,152.15	416.41

Consumption of Packing Material is included in the consumption of Raw material.

19 Change in Inventories of work in progress and finished goods

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Opening Inventories		
Finished Goods	27.85	-
Work-in-progress	101.97	-
Less: Closing Inventories		
Finished Goods	77.56	27.85
Work-in-progress	147.64	101.97
Total	(95.38)	(129.83)

20 Employee benefit expenses

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Salaries and wages	21.54	17.49
Bonus Expense	1.81	0.70
Directors Remuneration	22.30	8.10
Total	45.65	26.29

Notes forming part of the Financial Statements

21 Finance costs

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Interest expense		
-Interest on CC	10.09	4.89
-Interest on Director's Loan	8.24	8.06
-Interest on Termloan	9.51	9.18
Bank Charges	0.71	0.22
Bank Loan Charges	6.94	1.57
Penal Interest	-	0.02
Total	35.49	23.94

22 Depreciation and amortization expenses

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Depreciation on property, plant and equipment	22.14	24.12
Total	22.14	24.12

Depreciation is calculated using the Written Down Value (WDV) method, in accordance with the rates derived from the useful lives of assets as prescribed in Schedule II of the Companies Act, 2013.

23 Other expenses

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Auditors' Remuneration	1.00	0.40
Commission	0.79	0.68
Consultancy fees	0.72	0.38
Direct expenses		
-Electricity Expense	8.29	7.30
-GAS Expense	0.38	0.45
-Labour Expense	56.93	34.08
-Packing & Forwarding Expenses	-	0.23
-Product Approval Charges	0.70	1.12
-Repair & Maintenance Expenses	2.03	4.12
-Testing Expenses	0.32	0.08
-Transportation Expense	3.18	2.80
-Water Expenses	0.96	0.93
Insurance	1.29	0.39
Professional fees		
-Director's Professional Fees	8.25	-
-Professional Fees	2.08	2.62
Rent	16.40	15.62
Repairs to buildings	0.82	0.92
Repairs to machinery	0.50	-
Travelling Expenses	1.84	-
Apron Expense	0.51	-
Business Expenses	-	3.40
Cash Discount Given	0.34	-
Cleaning Expense	0.09	0.77
Courier & Transport Chrges	3.72	0.48
Total continued	111.14	76.77

Notes forming part of the Financial Statements

Other expenses		(Rs in lacs)	
Particulars	31 March 2025	31 March 2024	
Total continued from previous page	111.14	76.77	
Discount Expenses	-	0.09	
Documentation Charges	0.34	-	
Domain Expense	-	0.11	
Foreign Exchange Loss/gain	(0.06)	-	
Government Fees	8.10	-	
GST Expense	0.25	0.39	
Job Work Services	-	0.17	
Membership Fees	0.51	-	
Office Expense	1.04	0.44	
Packing & Forwarding Expenses	-	0.03	
Product Permission Expense	-	0.14	
Refreshment Expenses	0.38	0.58	
Registration Fees	0.24	0.41	
Software Expense	-	0.12	
Stamp Duty Expense	0.27	0.13	
Stationery & Printing Expenses	0.44	1.05	
Statutory Expenses	0.47	-	
Tender Fees	-	0.05	
Transportation Expense	0.09	-	
Wastage Expense	0.77	-	
Water Expenses	1.44	0.61	
Total	125.42	81.09	

24 Tax Expenses		(Rs in lacs)	
Particulars	31 March 2025	31 March 2024	
Current Tax	53.72	-	
Deferred Tax	0.15	(1.05)	
Excess/Short Provision Written back/off	11.37	-	
Total	65.24	(1.05)	

Significant components of Deferred Tax charged during the year		(Rs in lacs)	
Particulars	31 March 2025	31 March 2024	
Difference between book depreciation and tax depreciation	0.15	(1.05)	
Total	0.15	(1.05)	

During the current year, Tax expense amounting to Rs. 11,37,375, is pertaining to the FY 2023-24, which is paid during the year and recorded as Excess/ (short) provision under the Tax Expense head of the Profit and Loss statement.

Notes forming part of the Financial Statements

25 Earning per share

Particulars	31 March 2025	31 March 2024
Profit attributable to equity shareholders (Rs in lacs)	250.09	72.33
Weighted average number of Equity Shares	363,364	360,000
Earnings per share basic (Rs)	68.83	20.09
Earnings per share diluted (Rs)	68.83	20.09
Face value per equity share (Rs)	10	10

During the Year, company has issued equity shares of 127000 amounting to Rs.130 (Having Face value of Rs. 10). EPS is calculated by dividing distributable Profit to the share holders with the weighted average equity shares outstanding at the end of balance sheet date.

26 Auditors' Remuneration

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Payments to auditor as		
- Audit Fees	1.00	0.40
Total	1.00	0.40

27 Earnings in Foreign Currencies

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Export of Goods calculated on FOB basis	54.01	9.34
Total	54.01	9.34

27 Segment Reporting Other Information

(Rs in lacs)

Particulars	Capital Expenditure		Depreciation		Non-cash expenses other than depreciation	
	31 March 2025	31 March 2024	31 March 2025	31 March 2024	31 March 2025	31 March 2024
Total	-	-	-	-	-	-

Additional Information by Geographies

(Rs in lacs)

Particulars	31 March 2025	31 March 2024
Revenue by Geographical Market		
In India	1,546.17	491.18
Outside India	54.01	9.34
Total	1,600.18	500.52

28 Related Party Disclosure

(i) List of Related Parties

Name	Relationship
Harshad Nanubhai Rathod	Key Managerial Personnel (Director)
Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)
Mayur Popatlal Sojitra	Key Managerial Personnel (Director)
Vivek Ashokkumar Patel	Key Managerial Personnel (Director)
Ankurkumar Shantilal Patel	Key Managerial Personnel (Director)
Paraskumar Vinubhai Parmar	Key Managerial Personnel (Director)
Accretion Pharmaceuticals Limited	Firm where Directors are interested
Accretion Inc	Firm where Directors are interested
Accretion Pharmaceuticals	Firm where Directors are interested
Pooja Harshad Rathod	Relative of KMP (Director)
Shweta Mayur Sojitra	Relative of KMP (Director)
Vaishakhi Hardik Prajapati	Relative of KMP (Director)
Ankita Vivek Patel	Relative of KMP (Director)

Notes forming part of the Financial Statements

(ii) Related Party Transactions

(Rs in lacs)

Particulars	Relationship	31 March 2025	31 March 2024
Loan Received			
- Harshad Nanubhai Rathod	Key Managerial Personnel (Director)	1.45	3.00
- Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)	0.45	-
- Mayur Popatlal Sojitra	Key Managerial Personnel (Director)	0.45	-
- Vivek Ashokkumar Patel	Key Managerial Personnel (Director)	0.45	5.00
- Ankurkumar Shantilal Patel	Key Managerial Personnel (Director)	0.60	-
Loan Repaid			
- Harshad Nanubhai Rathod	Key Managerial Personnel (Director)	18.11	3.00
- Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)	17.11	-
- Mayur Popatlal Sojitra	Key Managerial Personnel (Director)	17.11	-
- Vivek Ashokkumar Patel	Key Managerial Personnel (Director)	17.11	5.00
- Ankurkumar Shantilal Patel	Key Managerial Personnel (Director)	17.26	-
Interest on Loan			
- Harshad Nanubhai Rathod	Key Managerial Personnel (Director)	1.65	1.61
- Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)	1.65	1.61
- Mayur Popatlal Sojitra	Key Managerial Personnel (Director)	1.65	1.61
- Vivek Ashokkumar Patel	Key Managerial Personnel (Director)	1.65	1.61
- Ankurkumar Shantilal Patel	Key Managerial Personnel (Director)	1.65	1.61
Director Remuneration			
- Harshad Nanubhai Rathod	Key Managerial Personnel (Director)	0.90	0.90
- Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)	4.65	0.90
- Mayur Popatlal Sojitra	Key Managerial Personnel (Director)	5.25	0.90
- Vivek Ashokkumar Patel	Key Managerial Personnel (Director)	0.90	0.90
- Ankurkumar Shantilal Patel	Key Managerial Personnel (Director)	7.80	4.50
- Paraskumar Vinubhai Parmar	Key Managerial Personnel (Director)	2.80	-
Sales			
- Accretion Inc	Firm where Directors are interested	11.16	6.14
- Accretion Pharmaceuticals Limited	Firm where Directors are interested	24.23	39.38
Purchase			
- Accretion Inc	Firm where Directors are interested	11.41	-
- Accretion Pharmaceuticals Limited	Firm where Directors are interested	77.97	44.36
Director Professional Fees			
- Harshad Nanubhai Rathod	Key Managerial Personnel (Director)	3.71	-
- Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)	0.60	-
- Vivek Ashokkumar Patel	Key Managerial Personnel (Director)	3.71	-

(iii) Related Party Balances

(Rs in lacs)

Particulars	Relationship	31 March 2025	31 March 2024
Sundry Creditors			
- Accretion Pharmaceuticals Limited	Firm where Directors are interested	-	0.02
Unsecured Loan			
- Harshad Nanubhai Rathod	Key Managerial Personnel (Director)	-	15.01
- Hardik Mukundbhai Prajapati	Key Managerial Personnel (Director)	-	15.01
- Mayur Popatlal Sojitra	Key Managerial Personnel (Director)	-	15.01
- Vivek Ashokkumar Patel	Key Managerial Personnel (Director)	-	15.01
- Ankurkumar Shantilal Patel	Key Managerial Personnel (Director)	-	15.01

Notes forming part of the Financial Statements

29 Ratio Analysis

Particulars	Numerator/Denominator	31 March 2025	31 March 2024	Change in %
(a) Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	2.87	1.14	152.14%
(b) Debt-Equity Ratio	$\frac{\text{Total Debts}}{\text{Shareholder's Equity}}$	0.76	2.42	-68.38%
(c) Debt Service Coverage Ratio	$\frac{\text{Earning available for Debt Service}}{\text{Debt Service}}$	3.11	2.86	8.50%
(d) Return on Equity Ratio	$\frac{\text{Profit after Tax}}{\text{Closing Shareholder's Equity}}$	49.50%	80.37%	-38.40%
(e) Inventory turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Inventories}}$	3.49	2.10	65.73%
(f) Trade receivables turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Trade Receivable}}$	4.90	20.06	-75.57%
(g) Trade payables turnover ratio	$\frac{\text{Total Purchases}}{\text{Closing Trade Payable}}$	14.33	4.44	223.04%
(h) Net capital turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Working Capital}}$	2.82	12.91	-78.16%
(i) Net profit ratio	$\frac{\text{Net Profit}}{\text{Total Turnover}}$	15.63%	14.45%	8.15%
(j) Return on Capital employed	$\frac{\text{Earning before interest and taxes}}{\text{Capital Employed}}$	39.37%	30.98%	27.08%
(k) Return on investment	$\frac{\text{Return on Investment}}{\text{Total Investment}}$	0.00%	0.00%	

Note:

i. Earning available for Debt Service = Net Profit before taxes + Non-cash operating expenses + Interest + other exceptional item

ii. Debt service = Interest & Lease Payments + Principal Repayments

iii. Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability

Reasons for Variances

- 1) Current Ratio : In comparison with the current liabilities there is increase in Inventory and in Trade receivable. Hence, variance incurred.
- 2) Debt Equity Ratio: In compare to increase in Loan amount there is higher increase in share holder fund. hence, variance incurred.
- 3) Return on equity ratio: In compare to previous there is an increase in share capital fund and increase in profit after tax (due to increase in business in compare to previous year), variance incurred.
- 4) Inventory Turnover Ratio: In compare to previous year there is higher increase in inventory holding and increase in total turnover of the company.
- 5) Trade Receivable Turnover: In current year there is higher increase in turnover and in compare to that there is lower collection, hence variance incurred.
- 6) Trade Payable Turnover ratio: In comparison to previous year, company is making an efficient payments to its creditor. Hence, positive variance incurred.
- 7) Net Capital Turnover ratio: In compare to previous year, there is increase in turn over and increase in working capital of the company, hence variance incurred.
- 8) Return on Capital Employed: There is increase in earning of the company in comparison with the previous year, hence variance incurred.

30 Other Statutory Disclosures as per the Companies Act, 2013

1. Title deeds of Immovable Property are held in name of the Company.
2. The Company has not granted any Loans or Advances in the nature of loans to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are (a) repayable on demand or (b) without specifying any terms or period of repayment.
3. The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
4. The Company has not declared willful defaulter by any bank or financial institution or other lender.
5. Based on the information available with the Company, the Company does not have any transactions with companies struck off u/s 248 of the Companies Act, 2013.
6. The Company has not traded or invested in Crypto currency or Virtual Currency during the audited period.
7. The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
8. The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
9. The Company has not entered into any such transaction which is not recorded in the books of account that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
10. The Company has not entered into any scheme of arrangement therefore approval of competent authority in terms of sections 230 to 237 of the Companies Act, 2013 is not required.
11. The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.

Regrouping

- 31.1. The figures of the previous year have been re-arranged, re-grouped and re-classified wherever necessary.
2. Trade payable and Trade receivable balances are re-grouped according to its nature of transactions and accordingly previous year ageing is also regrouped accordingly. As per our report of even date.

As per our report of even date
For M/s V S S B & Associates
Chartered Accountants
Firm's Registration No. 0121356W

For and on behalf of the Board of
ACCRETION NUTRAVEDA LIMITED

Vishves A. Shah
Partner
Membership No. 109944

Harshad Rathod
Director
DIN: 09108392

Vivek Patel
Director
DIN: 09130357

UDIN: 25109944BMGPOH9829
Place: Ahmedabad
Date: 23 July 2025

Place: Ahmedabad
Date: 23 July 2025

COMPANY INFORMATION

BOARD OF DIRECTORS

VIVEK ASHOK KUMAR PATEL

PROMOTER DIRECTOR

ANKURKUMAR SHANTILAL PATEL

PROMOTER DIRECTOR

HARSHAD NANUBHAI RATHOD

PROMOTER DIRECTOR

HARDIK MUKUNDBHAI PRAJAPATI

PROMOTER DIRECTOR

MAYUR POPATLAL SOJITRA

PROMOTER DIRECTOR

PARASKUMAR VINUBHAI PARMAR

Additional Director

(Appointed w.e.f. 17/02/2025) and
Chief Financial Officer (Appointed w.e.f. 11/09/2025)

COMPANY SECRETARY

Payal Hareshbhai Kotadiya

COMPANY SECRETARY
(Appointed w.e.f. 06/09/2025)

STATUTORY AUDITOR

M/s. V S S B & Associates

CHARTERED ACCOUNTANTS
A/912, 9th Floor, Ratnaakar Nine Square, Opp. Keshavbaug Party Plot,
Vastrapur, Ahmedabad - 380015, Gujarat, India.

REGISTERED OFFICE

ACCRETION NUTRAVEDA LIMITED

CIN: U24290GJ2021PLC121216

PAN: AAUCA9884F

Registered Office: 27 Xcelon Industrial Park-1, Vasna-Chacharwadi,
Ta- Sanand, Ahmedabad-382213, Gujarat, India.

E-Mail: compliance@accretionnutraveda.com

NOTICE

SHORTER NOTICE is hereby given that the 4th Annual General Meeting of the Members of Accretion Nutraveda Limited will be held on Thursday, 11th September, 2025 at 04:00 P.M. at the registered office of the company situated at 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta- Sanand, Ahmedabad-382213, Gujarat, India to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider, approve and adopt the Financial Statements of the Company for the year ended March 31, 2025, including audited Balance Sheet as at March 31, 2025 and Statement of Profit & Loss Account and Cash Flow statement for the year ended on that date together with the Report of the Auditor's and Director's thereon.
2. To appoint a director in place of Mr. Harshad Nanubhai Rathod (DIN: 09108392), who retires by rotation and being eligible, offers himself for re-appointment.

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant the provisions of Section 152 (6) of the Companies Act, 2013 Mr. Harshad Nanubhai Rathod (DIN: 09108392), who retires by rotation, and being eligible, offers himself for re-appointment, be and is hereby re-appointed as a director of the Company, liable to retire by rotation."

3. Appointment of M/s. V S S B & ASSOCIATES [ICAI Firm Registration No.: 121356W], Chartered Accountants, as Statutory Auditor:

To pass following resolution, with or without modification, as Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), the Company hereby appoint M/s V S S B & ASSOCIATES [ICAI Firm Registration No.: 121356W], Chartered Accountants, as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the 9th Annual General Meeting of the company to be held for the financial year 2029-30, at a remuneration as may be decided by the Board of Directors in consultation with the Auditors, plus applicable taxes."

SPECIAL BUSINESS:

4. Regularization of Appointment of Mr. Paraskumar Vinubhai Parmar (DIN: 10952040) As an Executive Director

To pass following resolution, with or without modification, as an Ordinary Resolution:

"RESOLVED THAT pursuant to Section 160 and other applicable provisions of the Companies Act, 2013 and rules made thereunder, Mr. Paraskumar Vinubhai Parmar [DIN: 10952040] in respect of whom the Company has received a notice in writing from a member under Section 160 of the Companies Act, 2013 signifying his intention to propose, Mr. Paraskumar Vinubhai Parmar [DIN: 10952040] as a candidate for the office of the director of the Company, be and is hereby appointed as a Director of the Company"

"RESOLVED THAT pursuant to the provisions of Section 2(54), 203 read with Schedule V and all other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Appointment and Remuneration of Managerial Person) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and in accordance with relevant clause of the Articles of Association of the Company, consent of Members of the Company be and is hereby accorded for appointment of Mr. Paraskumar Vinubhai Parmar [DIN: 10952040] as executive Director of the company, to oversight the compliances of all financial matter and other compliances, rules and regulations as may be applicable to the Company from time to time, of the Company and who has consented to act as such and shall be liable to retire by rotation on terms and conditions set out in the Explanatory Statement annexed to the Notice convening this Meeting;

RESOLVED FURTHER THAT the terms and the remuneration as set out in the Explanatory Statement annexed to the Notice convening this Meeting shall be deemed to form part hereof and in the event of inadequacy or absence of profits, the remuneration comprising salary, perquisites and benefits approved by the Board of Directors be paid as minimum remuneration to Director;

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to alter and vary the terms and conditions of appointment and / or remuneration, within limits permissible under the Act and, and execute all such documents, instruments and writings as may be required to give effect to the aforesaid Resolution in such manner as may be agreed between the Board and Mr. Paraskumar Vinubhai Parmar."

5. Change in designation of Mr. Mayur Popatlal Sojitra (DIN: 09108404) as Managing Director of the company and Revision in terms of Remuneration.

To consider and, if thought fit, to pass the following resolution as a Special **Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 2(54), 196, 197, 203 read with Schedule V and all other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Appointment and Remuneration of Managerial Person) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and in accordance with relevant clause of the Articles of Association of the Company, consent of Members of the Company be and is hereby accorded for appointment of Mr. Mayur Popatlal Sojitra (DIN: 09108404) as Managing Director of the company to oversee and manage the day to day affairs of the Company and who has consented to act as such, for a period of 5 (Five) years commencing from 11/09/2025 and ending 10/09/2030 and shall not be liable to retire by rotation on terms and conditions set out in the Explanatory Statement annexed to the Notice convening this Meeting;

RESOLVED FURTHER THAT the terms and the remuneration as set out in the Explanatory Statement annexed to the Notice convening this Meeting shall be deemed to form part hereof and in the event of inadequacy or absence of profits, the remuneration comprising salary, perquisites and benefits approved by the Board of Directors be paid as minimum remuneration to the Managing Director;

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to alter and vary the terms and conditions of appointment and / or remuneration, within limits permissible under the Act and, and execute all such documents, instruments and writings as may be required to give effect to the aforesaid Resolution in such manner as may be agreed between the Board and Mr. Mayur Popatlal Sojitra.

6. Change in designation of Mr. Ankurkumar Shantilal Patel (DIN: 09130391) as Whole-time Director of the company and Revision in terms of Remuneration.

To consider and, if thought fit, to pass the following resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Section 2(54), 196, 197, 203 read with Schedule V and all other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Appointment and Remuneration of Managerial Person) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and in accordance with relevant clause of the Articles of Association of the Company, consent of Members of the Company be and is hereby accorded for appointment of Mr. Ankurkumar Shantilal Patel (DIN: 09130391) as Whole-time Director of the company to oversee and manage the day to day affairs of the Company and who has consented to act as such, for a period of 5 (Five) years commencing from 11/09/2025 and ending 10/09/2030 and shall not be liable to retire by rotation on terms and conditions set out in the Explanatory Statement annexed to the Notice convening this Meeting;

RESOLVED FURTHER THAT the terms and the remuneration as set out in the Explanatory Statement annexed to the Notice convening this Meeting shall be deemed to form part hereof and in the event of inadequacy or absence of profits, the remuneration comprising salary, perquisites and benefits approved by the Board of Directors be paid as minimum remuneration to the Whole-time Director;

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to alter and vary the terms and conditions of appointment and / or remuneration, within limits permissible under the Act and, and execute all such documents, instruments and writings as may be required to give effect to the aforesaid Resolution in such manner as may be agreed between the Board and Mr. Ankurkumar Shantilal Patel.

7. Revision in terms of Appointment and Remuneration of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403) as Non-Executive Director of the company.

To consider and, if thought fit, to pass the following resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 read with applicable rules [including any statutory modification(s) or re-enactment(s) thereof for the time being in force], as amended from time to time, and approval of the Board of Directors of the Company, the consent of the Members be and is hereby accorded to vary/modify the terms of appointment of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), Non-Executive Director of the Company, who was earlier appointed as a Director not liable to retire by rotation, and that henceforth, he shall be liable to retire by rotation.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197, 198 read with Schedule V and all other applicable provisions of the Companies Act, 2013 read with the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification or re-enactment(s) thereof for the time being in force) and approval of Board of Directors, consent of Members of the Company be and is hereby accorded for the revision in remuneration payable to Mr. Hardik Mukundbhai Prajapati (DIN: 09108403) as set out in the Explanatory Statement to this Notice.

RESOLVED FURTHER THAT in terms of the applicable provisions of Section 197(3) of the Companies Act, 2013 ("The Act") and Schedule V of the Act, were in any financial year during the tenure of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), the Company has no profit or its profit is inadequate, the Company shall pay Mr. Hardik Mukundbhai Prajapati, the remuneration comprising of salary, perquisites and other benefits and emoluments as specified in the Explanatory Statement annexed to this Notice as minimum remuneration.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do and perform all such acts, deeds and things as may be necessary, desirable or expedient to give effect to this resolution."

8. Revision in terms of Appointment and Remuneration of Mr. Harshad Nanubhai Rathod (DIN: 09108392) as Non-Executive Director of the company.

To consider and, if thought fit, to pass the following resolution as **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 read with applicable rules [including any statutory modification(s) or re-enactment(s) thereof for the time being in force], as amended from time to time, and approval of the Board of Directors of the Company, the consent of the Members be and is hereby accorded to vary/modify the terms of appointment of Mr. Harshad Nanubhai Rathod (DIN: 09108392), Non-Executive Director of the Company, who was earlier appointed as a Director not liable to retire by rotation, and that henceforth, he shall be liable to retire by rotation.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197, 198 read with Schedule V and all other applicable provisions of the Companies Act, 2013 read with the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification or re-enactment(s) thereof for the time being in force) and approval of Board of Directors, consent of Members of the Company be and is hereby accorded for the revision in remuneration payable to Mr. Harshad Nanubhai Rathod (DIN: 09108392) as set out in the Explanatory Statement to this Notice.

RESOLVED FURTHER THAT in terms of the applicable provisions of Section 197(3) of the Companies Act, 2013 ("The Act") and Schedule V of the Act, were in any financial year during the tenure of Mr. Harshad Nanubhai Rathod (DIN: 09108392), the Company has no profit or its profit is inadequate, the Company shall pay Mr. Harshad Nanubhai Rathod, the remuneration comprising of salary, perquisites and other benefits and emoluments as specified in the Explanatory Statement annexed to this Notice as minimum remuneration.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do and perform all such acts, deeds and things as may be necessary, desirable or expedient to give effect to this resolution."

9. Revision in terms of Appointment and Remuneration of Mr. Vivek Ashok Kumar Patel (DIN: 09130357) as Non-Executive Director of the company.

To consider and, if thought fit, to pass the following resolution as Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 read with applicable rules [including any statutory modification(s) or re-enactment(s) thereof for the time being in force], as amended from time to time, and approval of the Board of Directors of the Company, the consent of the Members be and is hereby accorded to vary/modify the terms of appointment of Mr. Vivek Ashok Kumar Patel (DIN: 09130357), Non-Executive Director of the Company, who was earlier appointed as a Director not liable to retire by rotation, and that henceforth, he shall be liable to retire by rotation.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197, 198 read with Schedule V and all other applicable provisions of the Companies Act, 2013 read with the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification or re-enactment(s) thereof for the time being in force) and approval of Board of Directors, consent of Members of the Company be and is hereby accorded for the revision in remuneration payable to Mr. Vivek Ashok Kumar Patel (DIN: 09130357) as set out in the Explanatory Statement to this Notice.

RESOLVED FURTHER THAT in terms of the applicable provisions of Section 197(3) of the Companies Act, 2013 (“The Act”) and Schedule V of the Act, were in any financial year during the tenure of Mr. Vivek Ashok Kumar Patel (DIN: 09130357), the Company has no profit or its profit is inadequate, the Company shall pay Mr. Vivek Ashok Kumar Patel, the remuneration comprising of salary, perquisites and other benefits and emoluments as specified in the Explanatory Statement annexed to this Notice as minimum remuneration.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do and perform all such acts, deeds and things as may be necessary, desirable or expedient to give effect to this resolution.”

10. To consider and approve the appointment of Mr. Arun Dash as Professional Independent Director of the Company

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** in accordance with the provisions of Sections 149, 150, 160 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (“Act”) and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Consent of members be and is hereby accorded to appoint Mr. Arun Das (DIN: 09657537) as an independent Director of the company with effect from 11/09/2025 and in respect of whom the Company has received a notice in writing from a member signifying his intention to propose him as a candidate for the office of the Director, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation to hold office for a period of five years with effect from 11/09/2025 till 10/09/2030;

RESOLVED FURTHER THAT the Board of Directors of the Company (which includes any Committee of the Board) be and are hereby authorized to do all necessary acts, deeds, things and execute all such documents, undertaking as may be necessary in this regard from time to time to give effect to the above resolution.”

11. To consider and approve the appointment of Mr. Mahipal Singh Chouhan as Professional Independent Director of the Company.

To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED THAT in accordance with the provisions of Sections 149, 150, 160 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 ("Act") and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Consent of members be and is hereby accorded to appoint Mr. Mahipal Singh Chouhan (DIN: 08977710) as an independent Director of the company with effect from 11/09/2025 and in respect of whom the Company has received a notice in writing from a member signifying his intention to propose him as a candidate for the office of the Director, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation to hold office for a period of five years with effect from 11/09/2025 till 10/09/2030;

RESOLVED FURTHER THAT the Board of Directors of the Company (which includes any Committee of the Board) be and are hereby authorized to do all necessary acts, deeds, things and execute all such documents, undertaking as may be necessary in this regard from time to time to give effect to the above resolution."

12. To consider and approve the appointment of Ms. Shruti Gupta as Professional Independent Director of the Company

To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED THAT in accordance with the provisions of Sections 149, 150, 160 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 ("Act") and the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Consent of members be and is hereby accorded to appoint Ms. Shruti Gupta (DIN: 10310259) as an independent Director of the company with effect from 11/09/2025 and in respect of whom the Company has received a notice in writing from a member signifying his intention to propose him as a candidate for the office of the Director, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation to hold office for a period of five years with effect from 11/09/2025 till 10/09/2030;

RESOLVED FURTHER THAT the Board of Directors of the Company (which includes any Committee of the Board) be and are hereby authorized to do all necessary acts, deeds, things and execute all such documents, undertaking as may be necessary in this regard from time to time to give effect to the above resolution."

13. To consider and approve Increase in Authorised capital of the Company.

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Section 61, Section 64 and other applicable provisions, if any, of the Companies Act, 2013, and Rule 15 of the Companies (Share capital and Debentures) Rules, 2014 and as per the Articles of Association of the Company, consent of the members, be and is hereby accorded to increase the Authorized Share Capital of the Company from Rs. 6,00,00,000/- (Rupees Six Crores Only) divided into 60,00,000 Equity shares of Rs. 10 each to Rs. 8,00,00,000/- (Rupees Eight Crores Only) divided into 80,00,000 Equity shares of Rs. 10 each.

RESOLVED FURTHER THAT pursuant to the provisions of Section 13 and all other applicable provisions of the Companies Act, 2013 and the relevant rules framed thereunder, the Capital Clause (Clause 5) of the Memorandum of Association of the Company is substituted with the following Clause 5:

5. The Share Capital of the Company is 8,00,00,000 Rupees, divided into 80,00,000 Equity Shares of 10 rupees each.

RESOLVED FURTHER THAT the Board of Directors of the Company (which includes any Committee of the Board) be and are hereby authorized to do all necessary acts, deeds, things and execute all such documents, undertaking as may be necessary in this regard from time to time to give effect to the above resolution.”

14. To consider and approve Public issue.

To consider and, if thought fit, to pass the following resolution as an Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 23 and 62(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013 (hereinafter referred to as the “Act”) (including any statutory modification or re-enactment thereof for the time being in force), read with the Memorandum of Association and Articles of Association of the Company and the Listing Agreements to be entered into with the respective stock exchange, where the Company's equity shares are proposed to be listed and subject to the approval to the extent necessary of the Government of India (“GOI”), Securities and Exchange Board of India (“SEBI”), Reserve Bank of India (“RBI”) and all other concerned statutory and other authorities, as may be required (hereinafter collectively referred to as “Appropriate Authority”) and to the extent necessary, such other approvals, consents, permissions, sanctions and the like, as may be necessary, and subject to such conditions and modifications as may be prescribed, stipulated or imposed by any of them while granting such approvals, consents, permissions, sanctions and the like, which may be agreed to by the Board of Directors of the Company, the approval of the Members of the Company be and is hereby accorded to the Board of Directors to create, offer, issue and allot equity shares of an aggregate number up to and not exceeding 19,20,000 Equity Shares (the “Fresh Issue”) at a price as may be decided by the Board of Directors in consultation with Lead Manager, ranking Pari-passu with the existing equity shares of the Company, to such person or persons who may or may not be the shareholders of the Company as the Board may decide, including anchor investors, if any, one or more of the members of the Company, employees (through a reservation or otherwise), Hindu Undivided Families, foreign portfolio investors, venture capital funds, alternative investment funds, foreign venture capital investors, multilateral and bilateral financial institutions, non-resident Indians, state industrial development corporations, insurance companies, provident funds, pension funds, the National Investment Fund, insurance funds set up by army, navy, or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India, trusts/societies registered under the Societies Registration Act, 1860, development financial institutions, systemically important non-banking financial companies, Indian mutual funds, members of group companies, Indian public, bodies corporate, companies (private or public) or other entities (whether incorporated or not), authorities, and to such other persons including high net worth individuals, retail individual bidders or other entities in one or more combinations thereof and/or any other category of investors as may be permitted to invest under Applicable Laws by way of initial public offering including General Public their friends, relatives and associates, foreign/ resident investors, financial institutions, venture capital funds, public financial institutions, banks, multilateral and bilateral development financial institutions, insurance whether they be holders of equity shares of the Company or not, and/or through issue of offer documents (“Initial Public Offer”) / Allotment regulations of SEBI, through the book built Issue, in one or more tranches and in the manner, and on the terms and conditions, as the Board may in its absolute sole discretion, decide including the price at which the equity shares are to be issued, at par or at premium and for cash and the decision to determine the category or categories of investors to whom the offer, issue and allotment/transfer shall be made to the exclusion of all other categories of investors on such terms and conditions as may be finalized by the Board and that the Board may finalize all matters incidental thereto as it may in its absolute discretion think fit;

RESOLVED FURTHER THAT the Board, be and is hereby authorized to make any alteration, addition or vary any of the above said clauses, in consultation with the Lead Manager or such other authorities as may be required, and without prejudice to the generality of the aforesaid, deciding the exact Issue structure, and on the exact component of fresh issue of shares in the Issue."

RESOLVED FURTHER THAT: -

- a) All the monies received out of the issue of shares to the public shall be transferred to separate bank account referred to in Sub-section (3) of Section 40 of the Companies Act, 2013;
- b) Details of all monies utilized out of the Issue referred to in sub-item (a) above shall be disclosed under an appropriate separate head in the balance sheet of the Company indicating the purpose for which such monies had been utilized; and
- c) Details of all unutilized monies out of the issue of shares, if any, referred to in sub-item (a) above shall be disclosed under an appropriate separate head in the balance sheet of the Company indicating the form in which such unutilized monies have been invested;

RESOLVED FURTHER THAT such of these equity shares to be issued as are not subscribed may be disposed of by the Board in favour of underwriter (s) to the issue;

RESOLVED FURTHER THAT the Board, be and is hereby authorized to take such action, give such directions, as may be necessary or desirable to give effect to this resolution and to do all such acts, matters, deeds and things, including but not limited to the allotment of equity shares against the valid applications received in the Initial Public Offering, as are in the best interests of the Company;

RESOLVED FURTHER THAT any one of the Director of the Company, be and is hereby authorized to execute and sign the documents including consent letter, power of attorney, certificates etc., as may be required in connection with the above;

RESOLVED FURTHER THAT the Board be and is hereby authorized to appoint the Lead Manager to the above Issue;

RESOLVED FURTHER THAT the Board be and is hereby authorized to appoint the Market Maker to the above Issue;

RESOLVED FURTHER THAT the Board be and is hereby authorized to appoint the Registrar to the Issue;

RESOLVED FURTHER THAT,

- a) The Company will furnish to the stock exchange on a quarterly/half yearly basis, a statement indicating material deviations, if any, in the use of proceeds of the Initial Public Offering from the objects stated in the Draft Prospectus/ Prospectus;
- b) The information mentioned in sub-clause (a) shall be furnished to the stock exchange along with the interim or annual financial results submitted under Regulation 33 of SEBI (LODR), 2015 and shall be published in the newspapers, if required simultaneously with the interim or annual financial results, after placing it before the Audit Committee, in terms of Regulation 47 of SEBI (LODR), 2015;

RESOLVED FURTHER THAT for the purpose of giving effect to these resolutions, the Board be and is hereby authorized, on behalf of the Company, to decide and approve the terms and conditions of the Issue, including but not limited to reservations for employees or other permitted categories, and shall be entitled to vary, modify or alter any of the terms and conditions, including the size of the Issue, as it may consider expedient and to do all such acts, deeds, matters and things, as it may in its absolute sole discretion deem necessary, proper, desirable and to settle any question, difficulty or doubt that may arise in regard to the above offer, issue and allotment and utilization of the proceeds of the Issue, to liaise with regulatory authorities and further to do all such acts, deeds, matters and things and to negotiate and finalize all such deeds, documents and writings as may be necessary, desirable or expedient to give effect to the above resolution and to negotiate terms, appoint advisor(s), lead manager, registrar(s), syndicate member(s), underwriter(s) any other intermediary/intermediaries registered with SEBI, legal counsel or legal experts, advertising agents/agencies, consultants and to pay any fees, commission, remuneration, incur expenses and take such further steps as may be required necessary, incidental or ancillary for the allotment and listing of the aforesaid equity shares on the Stock Exchanges (SME Segment) where the Company's equity shares are proposed to be listed, as may be decided by the Board, and to make such modifications without being required to seek further consents or approval of the members and that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution;

RESOLVED FURTHER THAT the Board be and is hereby authorized at its discretion, to further delegate by way of authorization in favor of any of the members of the Board to do all the necessary acts and take necessary steps that may be deemed expedient to give effect to this resolution.”

For and on Behalf of the Board of Directors of

ACCRETION NUTRAVEDA LIMITED

Harshad Nanubhai Rathod

Director

DIN: 09108392

Mayur Popatlal Sojitra

Director

DIN: 09108404

Place: Ahmedabad

Date: 11/09/2025

NOTES:

1. A member entitled to attend and vote at annual general meeting is entitled to appoint a proxy, to attend and vote at annual general meeting, and such proxy need not be a member of the company.
2. The proxies in order to be valid and effective must be delivered to the Company at the registered office of the company at least Forty-Eight hours before time for commencement of the meeting.
3. A person can act as proxy on behalf of members not exceeding 50 (fifty) and holding in aggregate not more than 10% of total share capital of the Company. In case of a member who is holding more than 10% of the total share capital of the Company may appoint a single person as proxy and such person shall not act as proxy for any other person or shareholder.
4. The instrument appointing proxy shall be duly signed by the appointer or his attorney duly authorized in writing, or if the appointer is a body corporate, it shall be under its seal or be signed by an officer or an attorney duly authorized by it.
5. Members are requested to intimate promptly change, if any, in their registered address at the registered office of the company.
6. Members/Proxies should bring attendance slip sent herewith duly filled in for attending the meeting.
7. Members desiring any information as regards the accounts are requested to write to the company at least 10 days before the date of the meeting, so as to enable the management to keep the information ready.
8. To promote green initiative, members are requested to register their e-mail addresses at registered office of the Company for sending the future communications by e-mail.
9. All documents referred to in the Notice or in the accompanying Explanatory Statement are available for inspection by the members at the Registered Office of the Company on all working days, except Saturdays, Sundays and public holidays, between 10.00 a.m. to 1.00 p.m. prior to the date of the Annual General Meeting and shall also be available for inspection at the meeting.
10. The relevant Explanatory Statement pursuant to Section 102 of Companies Act, 2013 in respect of the Special Business in the notice is annexed thereto.
11. Brief resume of the Directors seeking appointment and re-appointment as prescribed under the Secretarial Standards issued by the Institute of Company Secretaries of India is annexed hereto and forms part of the notice.

Explanatory Statement as required under Section 102 of the Companies Act, 2013

For Item No. 4

Mr. Paraskumar Vinubhai Parmar [DIN: 10952040], was appointed as Additional Director at meeting of board of directors held on 17/02/2025 whose term expire at ensuing Annual General Meeting and eligible for reappointment.

The Company has received notice in writing under provisions of the Section 160 of the Act, from a member proposing candidature of Mr. Paraskumar Vinubhai Parmar [DIN: 10952040], for the office of Director, to be appointed as such under provisions of the Section 160 of the Act.

The Board of Directors, at its meeting held on 11/09/2025, subject to approval of members, approved the appointment of Mr. Paraskumar Vinubhai Parmar [DIN: 10952040], as Director of the Company, on the terms and conditions, including the remuneration payable to Mr. Paraskumar Vinubhai Parmar, as contained in this explanatory statement.

The key factors that were considered by the Board while recommending the appointment of Mr. Paraskumar Vinubhai Parmar are given below:

He is a Director of Accretion Nutraved a Limited with professional experience in the pharmaceutical sector, specializing in business operations, financial planning, and strategic management. He holds a Bachelor of Pharmacy (B.Pharm) from Gujarat University, Ahmedabad, and a Master's degree in International Business (M.A.) from the University of Greenwich, London. His academic background and industry exposure enable him to contribute effectively to the company's growth and innovation in the nutraceutical and pharmaceutical space.

Mr. Paraskumar Vinubhai Parmar is neither disqualified from being appointed as a Director in terms of Section 164(2) read with Schedule V of the Act, nor debarred from holding the office of director by virtue of any SEBI order or any other such authority and has given all the necessary declarations and confirmation including his consent to be appointed as a Director of the Company

In terms of the provisions of Sections 196, 197, 198, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the rules made thereunder (including any statutory modification or re-enactment thereof for time being in force) and relevant provisions of Articles of Association of the Company, appointment of the Director requires approval of the Members.

Notwithstanding anything to the contrary herein contained, where in any financial year during the currency of the tenure of the above mention Directors, the Company has no profits or its profits are inadequate, the Company will pay remuneration to him by way of Salary, Benefits, Perquisites and Allowances, Commission and Incentive Remuneration as specified above in accordance with applicable law as the minimum remuneration.

The details of remuneration payable to Mr. Paraskumar Vinubhai Parmar, for the period 11/09/2025 to 10/09/2028 despite inadequacy or absence of profits is as under:

1.	Basic Salary	Not Exceeding Rs. 2,00,000 per month with such increases as may be determined by the Board from time to time as per the rules of the Company.
2.	Incentive and Variable Pay	As per the Policy of the Company
3.	Perquisites	As per the Policy of the Company
4.	Retirement benefits	Payable in accordance with the Rules of the Company and the Fund.

Such other allowances, perquisites, amenities, facilities and benefits as per the Rules of the Company as applicable to the Director as may be permitted and approved by the Board of Directors to be paid to the Director.

The Company has not defaulted in payment of dues to any bank or public financial institution or non-convertible debenture holders or other secured creditor, if any.

Except Mr. Paraskumar Vinubhai Parmar and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

Disclosures as required to be made to the members for payment of remuneration in case of inadequacy of profits in accordance with the provisions of Companies Act, 2013 and schedule V is set out below:

1. General Information:

1.	Nature of Industry	Engaged in Manufacturing and Trading of Pharmaceutical Products
2.	Date or expected date of commencement of commercial production	Company is operating since the day of its Incorporation
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4.	Financial performance based on given indicators	In the Financial year 2024-25, company has reported Turnover of Rs. 16,00,18,000 & has reported Net Profit after Tax of Rs. 2,50,09,000
5.	Foreign Investments or collaborations, if any	Not Applicable

2. Information about the appointee:

1.	Background details	As per Explanatory Statement attached to this Notice
2.	Past remuneration	Rs. 80,000 p.m.
3.	Recognition and awards	Nil
4.	Job profile and his sustainability	As per Explanatory Statement attached to this Notice
5.	Remuneration proposed	As per Explanatory Statement attached to this Notice
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration of Mr. Paraskumar Vinubhai Parmar is comparable to that drawn by the peers in the similar capacity in the industry and is commensurate with the size of the Company and diverse nature of its business
7.	Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Not related to any of the Directors and KMP of the Company

3. Other Information:

1.	Reasons of loss or inadequate profits	The Company is expected to achieve adequate profits. However, in case due to any uncertain event if company fails to achieve adequate profits it is desirable to take approval of shareholders as part of good corporate governance practice.
2.	Steps taken or proposed to be taken for improvement	The Company will take significant steps for the overall growth and development in case of inadequate profits.
3.	Expected increase in productivity and profits in measurable terms	The Company is expected to grow in coming years and directors of the Company plan to continue to tread the path of optimum utilization of resources resulting in increase in productivity, profit and overall growth.

Details of Directors seeking appointment/re-appointment at the Annual General Meeting Pursuant to Secretarial Standard on General Meetings (SS-2) is annexed and Marked as Annexure-1 to this Notice

The Board recommends the Special resolution set out in Item No. 4 for approval of Members.

Item No.: 5

The Board of Directors, at its meeting held on 11/09/2025, subject to approval of members, approved the appointment of Mr. Mayur Popatlal Sojitra as Managing Director designated as Managing Director of the Company for a period of 5 years i.e., from 11/09/2025 to 10/09/2030, on the terms and conditions, including the remuneration payable to Mr. Mayur Popatlal Sojitra, as contained in this explanatory statement.

The key factors that were considered by the Board while recommending the appointment of Mr. Mayur Popatlal Sojitra are given below:

- With a Bachelor's degree in Pharmacy from Gujarat University and an MBA in International Business from the University of Greenwich, London, he embodies strategic excellence. Boasting over 13 years of experience in the pharmaceutical industry, he crafts a bold vision for expanding into regulatory markets, guiding Accretion Nutraveda Limited toward global leadership with innovation and foresight.

Mr. Mayur Popatlal Sojitra is neither disqualified from being appointed as a Director in terms of Section 164(2) read with Schedule V of the Act, nor debarred from holding the office of director by virtue of any SEBI order or any other such authority and has given all the necessary declarations and confirmation including his consent to be appointed as a Managing Director of the Company

In terms of the provisions of Sections 196, 197, 198, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the rules made thereunder (including any statutory modification or re-enactment thereof for time being in force) and relevant provisions of Articles of Association of the Company, appointment of the Managing Director requires approval of the Members.

Notwithstanding anything to the contrary herein contained, where in any financial year during the currency of the tenure of the above mention Directors, the Company has no profits or its profits are inadequate, the Company will pay remuneration to him by way of Salary, Benefits, Perquisites and Allowances, Commission and Incentive Remuneration as specified above in accordance with applicable law as the minimum remuneration.

The details of remuneration payable to Mr. Mayur Popatlal Sojitra, for the period 11/09/2025 to 10/09/2028 despite inadequacy or absence of profits is as under:

1.	Basic Salary	Not Exceeding Rs. 2,00,000 per month with such increases as may be determined by the Board from time to time as per the rules of the Company.
2.	Incentive and Variable Pay	As per the Policy of the Company
3.	Perquisites	As per the Policy of the Company
4.	Retirement benefits	Payable in accordance with the Rules of the Company and the Fund.

Such other allowances, perquisites, amenities, facilities and benefits as per the Rules of the Company as applicable to the Director as may be permitted and approved by the Board of Directors to be paid to the Director.

The Company has not defaulted in payment of dues to any bank or public financial institution or non-convertible debenture holders or other secured creditor, if any.

Except Mr. Mayur Popatlal Sojitra and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

Disclosures as required to be made to the members for payment of remuneration in case of inadequacy of profits in accordance with the provisions of Companies Act, 2013 and schedule V is set out below:

Disclosures as required to be made to the members for payment of remuneration in case of inadequacy of profits in accordance with the provisions of Companies Act, 2013 and schedule V is set out below:

4. General Information:

1.	Nature of Industry	Engaged in Manufacturing and Trading of Pharmaceutical Products
2.	Date or expected date of commencement of commercial production	Company is operating since the day of its Incorporation
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4.	Financial performance based on given indicators	In the Financial year 2024-25, company has reported Turnover of Rs. 16,00,18,000 & has reported Net Profit after Tax of Rs. 2,50,09,000
5.	Foreign Investments or collaborations, if any	Not Applicable

5. Information about the appointee:

1.	Background details	As per Explanatory Statement attached to this Notice
2.	Past remuneration	Rs. 52,500 p.m.
3.	Recognition and awards	Nil
4.	Job profile and his sustainability	As per Explanatory Statement attached to this Notice
5.	Remuneration proposed	As per Explanatory Statement attached to this Notice
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration of Mr. Mayur Popatlal Sojitra is comparable to that drawn by the peers in the similar capacity in the industry and is commensurate with the size of the Company and diverse nature of its business
7.	Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Not related to any of the Directors and KMP of the Company

6. Other Information:

1.	Reasons of loss or inadequate profits	The Company is expected to achieve adequate profits. However, in case due to any uncertain event if company fails to achieve adequate profits it is desirable to take approval of shareholders as part of good corporate governance practice.
2.	Steps taken or proposed to be taken for improvement	The Company will take significant steps for the overall growth and development in case of inadequate profits.
3.	Expected increase in productivity and profits in measurable terms	The Company is expected to grow in coming years and directors of the Company plan to continue to tread the path of optimum utilization of resources resulting in increase in productivity, profit and overall growth.

Details of Directors seeking appointment/re-appointment at the Annual General Meeting Pursuant to Secretarial Standard on General Meetings (SS-2) is annexed and Marked as Annexure-1 to this Notice

The Board recommends the Special resolution set out in Item No. 5 for approval of Members.

Item No.: 6

The Board of Directors, at its meeting held on 11/09/2025, subject to approval of members, approved the appointment of Mr. Ankurkumar Shantilal Patel (DIN: 09130391) as Whole-time Director designated as Whole-time Director of the Company for a period of 5 years i.e., from 11/09/2025 to 10/09/2030, on the terms and conditions, including the remuneration payable to Mr. Ankurkumar Shantilal Patel, as contained in this explanatory statement.

The key factors that were considered by the Board while recommending the appointment of Mr. Ankurkumar Shantilal Patel are given below:

Ankur Shantilal Patel is a Director of Accretion Nutraveda Limited with over 15 years of experience in the Herbal, Nutraceutical, and Ayurvedic industry. He has previously worked with leading companies such as Emami Limited, Sri Sri Ayurveda Trust, Vital Care Pvt. Ltd., and Sahajanand Life Sciences Pvt. Ltd. in roles spanning QA/QC, research, and R&D management. He holds a Bachelor of Pharmacy from L.J. Pharmacy College and a Master of Pharmacy in Ayurveda, bringing strong expertise in research, product development, and operational leadership.

Mr. Ankurkumar Shantilal Patel is neither disqualified from being appointed as a Director in terms of Section 164(2) read with Schedule V of the Act, nor debarred from holding the office of director by virtue of any SEBI order or any other such authority and has given all the necessary declarations and confirmation including his consent to be appointed as a Whole-time Director of the Company

In terms of the provisions of Sections 196, 197, 198, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the rules made thereunder (including any statutory modification or re-enactment thereof for time being in force) and relevant provisions of Articles of Association of the Company, appointment of the Managing Director requires approval of the Members.

Notwithstanding anything to the contrary herein contained, where in any financial year during the currency of the tenure of the above mention Directors, the Company has no profits or its profits are inadequate, the Company will pay remuneration to him by way of Salary, Benefits, Perquisites and Allowances, Commission and Incentive Remuneration as specified above in accordance with applicable law as the minimum remuneration.

The details of remuneration payable to Mr. Mayur Popatlal Sojitra, for the period 11/09/2025 to 10/09/2028 despite inadequacy or absence of profits is as under:

1.	Basic Salary	Not Exceeding Rs. 2,00,000 per month with such increases as may be determined by the Board from time to time as per the rules of the Company.
2.	Incentive and Variable Pay	As per the Policy of the Company
3.	Perquisites	As per the Policy of the Company
4.	Retirement benefits	Payable in accordance with the Rules of the Company and the Fund.

Such other allowances, perquisites, amenities, facilities and benefits as per the Rules of the Company as applicable to the Director as may be permitted and approved by the Board of Directors to be paid to the Director.

1. General Information:

1.	Nature of Industry	Engaged in Manufacturing and Trading of Pharmaceutical Products
2.	Date or expected date of commencement of commercial production	Company is operating since the day of its Incorporation
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4.	Financial performance based on given indicators	In the Financial year 2024-25, company has reported Turnover of Rs. 16,00,18,000 & has reported Net Profit after Tax of Rs. 2,50,09,000
5.	Foreign Investments or collaborations, if any	Not Applicable

2. Information about the appointee:

1.	Background details	As per Explanatory Statement attached to this Notice
2.	Past remuneration	Rs. 80,000 p.m.
3.	Recognition and awards	Nil
4.	Job profile and his sustainability	As per Explanatory Statement attached to this Notice
5.	Remuneration proposed	As per Explanatory Statement attached to this Notice
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration of Mr. Ankurkumar Shantilal Patel is comparable to that drawn by the peers in the similar capacity in the industry and is commensurate with the size of the Company and diverse nature of its business
7.	Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Not related to any of the Directors and KMP of the Company

3. Other Information:

1.	Reasons of loss or inadequate profits	The Company is expected to achieve adequate profits. However, in case due to any uncertain event if company fails to achieve adequate profits it is desirable to take approval of shareholders as part of good corporate governance practice.
2.	Steps taken or proposed to be taken for improvement	The Company will take significant steps for the overall growth and development in case of inadequate profits.
3.	Expected increase in productivity and profits in measurable terms	The Company is expected to grow in coming years and directors of the Company plan to continue to tread the path of optimum utilization of resources resulting in increase in productivity, profit and overall growth.

Details of Directors seeking appointment/re-appointment at the Annual General Meeting Pursuant to Secretarial Standard on General Meetings (SS-2) is annexed and Marked as Annexure-1 to this Notice

The Board recommends the Special resolution set out in Item No. 6 for approval of Members.

Item No.:7

Currently, Mr. Hardik Mukundbhai Prajapati (DIN: 09108403) serving company as Non-Executive Director of the Company. However, due to Mr. Hardik Mukundbhai Prajapati's multiple commitments and considering the executive responsibility that Mr. Hardik Mukundbhai Prajapati would assume and the Board of Directors at their meeting held on 11th September, 2025, proposed Revision in terms of Appointment and Remuneration of Mr. Hardik Mukundbhai Prajapati with effect from 11th September, 2025, subject to the approval of the

Board of Directors in view of the invaluable contribution of Mr. Hardik Mukundbhai Prajapati to the Company has approved to change his remuneration not exceeding Rs. 2,00,000 per month w.e.f. 11/09/2025 at their meeting held on 11/09/2025 subject to the approval of members on the terms and conditions as set out in this resolution.

In compliance with the provisions of 152, 196 and 197 read with schedule V of the Companies Act, 2013 and rules made there under change in remuneration of Mr. Hardik Mukundbhai Prajapati as specified above is now being placed before the Members for their approval.

Notwithstanding anything to the contrary herein contained, where in any financial year during the currency of the tenure of the above mention Directors, the Company has no profits or its profits are inadequate, the Company will pay remuneration to him by way of Salary, Benefits, Perquisites and Allowances, Commission and Incentive Remuneration as specified above in accordance with applicable law as the minimum remuneration.

Except Mr. Hardik Mukundbhai Prajapati and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

Disclosures as required to be made to the members for payment of remuneration in case of inadequacy of profits in accordance with the provisions of Companies Act, 2013 and schedule V is set out below:

1.	Basic Salary	Not Exceeding Rs. 2,00,000 per month with such increases as may be determined by the Board from time to time as per the rules of the Company.
2.	Incentive and Variable Pay	As per the Policy of the Company
3.	Perquisites	As per the Policy of the Company
4.	Retirement benefits	Payable in accordance with the Rules of the Company and the Fund.
Such other allowances, perquisites, amenities, facilities and benefits as per the Rules of the Company as applicable to the Non-Executive Director and as may be permitted and approved by the Board of Directors to be paid to the Non-Executive Director		

1. General Information:

1.	Nature of Industry	Engaged in Manufacturing and Trading of Pharmaceutical Products
2.	Date or expected date of commencement of commercial production	Company is operating since the day of its Incorporation
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4.	Financial performance based on given indicators	In the Financial year 2024-25, company has reported Turnover of Rs. 16,00,18,000 & has reported Net Profit after Tax of Rs. 2,50,09,000
5.	Foreign Investments or collaborations, if any	Not Applicable

2. Information about the appointee:

1.	Background details	As per Explanatory Statement attached to this Notice
2.	Past remuneration	Rs. 52,500 p.m.
3.	Recognition and awards	Nil
4.	Job profile and his sustainability	As per Explanatory Statement attached to this Notice
5.	Remuneration proposed	As per Explanatory Statement attached to this Notice
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration of Mr. Hardik Mukundbhai Prajapati is comparable to that drawn by the peers in the similar capacity in the industry and is commensurate with the size of the Company and diverse nature of its business
7.	Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Not related to any of the Directors and KMP of the Company

3. Other Information:

1.	Reasons of loss or inadequate profits	The Company is expected to achieve adequate profits. However, in case due to any uncertain event if company fails to achieve adequate profits it is desirable to take approval of shareholders as part of good corporate governance practice.
2.	Steps taken or proposed to be taken for improvement	The Company will take significant steps for the overall growth and development in case of inadequate profits.
3.	Expected increase in productivity and profits in measurable terms	The Company is expected to grow in coming years and directors of the Company plan to continue to tread the path of optimum utilization of resources resulting in increase in productivity, profit and overall growth.

Details of Directors seeking appointment/re-appointment at the Annual General Meeting Pursuant to Secretarial Standard on General Meetings (SS-2) is annexed and Marked as Annexure-1 to this Notice

The Board recommends the Special resolution set out in Item No. 7 for approval of Members.

Item No.: 8

Currently, Mr. Harshad Nanubhai Rathod (DIN: 09108392) serving company as Non-Executive Director of the Company. However, due to Mr. Harshad Nanubhai Rathod's multiple commitments and considering the executive responsibility that Mr. Harshad Nanubhai Rathod would assume and the Board of Directors at their meeting held on 11th September, 2025, proposed Revision in terms of Appointment and Remuneration of Mr. Harshad Nanubhai Rathod with effect from 11th September, 2025, subject to the approval of the Members.

Board of Directors in view of the invaluable contribution of Mr. Harshad Nanubhai Rathod to the Company has approved to change his remuneration not exceeding Rs. 2,00,000 per month w.e.f., 11/09/2025 at their meeting held on 11/09/2025 subject to the approval of members on the terms and conditions as set out in this resolution.

In compliance with the provisions of 152, 196 and 197 read with schedule V of the Companies Act, 2013 and rules made there under change in remuneration of Mr. Harshad Nanubhai Rathod as specified above is now being placed before the Members for their approval.

Notwithstanding anything to the contrary herein contained, where in any financial year during the currency of the tenure of the above mention Directors, the Company has no profits or its profits are inadequate, the Company will pay remuneration to him by way of Salary, Benefits, Perquisites and Allowances, Commission and Incentive Remuneration as specified above in accordance with applicable law as the minimum remuneration.

Except Mr. Harshad Nanubhai Rathod and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

Disclosures as required to be made to the members for payment of remuneration in case of inadequacy of profits in accordance with the provisions of Companies Act, 2013 and schedule V is set out below:

1.	Basic Salary	Not Exceeding Rs. 2,00,000 per month with such increases as may be determined by the Board from time to time as per the rules of the Company.
2.	Incentive and Variable Pay	As per the Policy of the Company
3.	Perquisites	As per the Policy of the Company
4.	Retirement benefits	Payable in accordance with the Rules of the Company and the Fund.
Such other allowances, perquisites, amenities, facilities and benefits as per the Rules of the Company as applicable to the Non-Executive Director and as may be permitted and approved by the Board of Directors to be paid to the Non-Executive Director		

1. General Information:

1.	Nature of Industry	Engaged in Manufacturing and Trading of Pharmaceutical Products
2.	Date or expected date of commencement of commercial production	Company is operating since the day of its Incorporation
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4.	Financial performance based on given indicators	In the Financial year 2024-25, company has reported Turnover of Rs. 16,00,18,000 & has reported Net Profit after Tax of Rs. 2,50,09,000
5.	Foreign Investments or collaborations, if any	Not Applicable

2. Information about the appointee:

1.	Background details	As per Explanatory Statement attached to this Notice
2.	Past remuneration	Rs. 52,500 p.m.
3.	Recognition and awards	Nil
4.	Job profile and his sustainability	As per Explanatory Statement attached to this Notice
5.	Remuneration proposed	As per Explanatory Statement attached to this Notice
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration of Mr. Harshad Nanubhai Rathod is comparable to that drawn by the peers in the similar capacity in the industry and is commensurate with the size of the Company and diverse nature of its business
7.	Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Not related to any of the Directors and KMP of the Company

3. Other Information:

1.	Reasons of loss or inadequate profits	The Company is expected to achieve adequate profits. However, in case due to any uncertain event if company fails to achieve adequate profits it is desirable to take approval of shareholders as part of good corporate governance practice.
2.	Steps taken or proposed to be taken for improvement	The Company will take significant steps for the overall growth and development in case of inadequate profits.
3.	Expected increase in productivity and profits in measurable terms	The Company is expected to grow in coming years and directors of the Company plan to continue to tread the path of optimum utilization of resources resulting in increase in productivity, profit and overall growth.

Details of Directors seeking appointment/re-appointment at the Annual General Meeting Pursuant to Secretarial Standard on General Meetings (SS-2) is annexed and Marked as Annexure-1 to this Notice

The Board recommends the Special resolution set out in Item No. 8 for approval of Members.

Item No.: 9

Currently, Mr. Vivek Ashok Kumar Patel (DIN: 09130357) serving company as Non-Executive Director of the Company. However, due to Mr. Vivek Ashok Kumar Patel's multiple commitments and considering the executive responsibility Mr. Vivek Ashok Kumar Patel would assume and the Board of Directors at their meeting held on 11th September, 2025, proposed Revision in terms of Appointment and Remuneration of Mr. Vivek Ashok Kumar Patel with effect from 11th September, 2025, subject to the approval of the Members.

Board of Directors in view of the invaluable contribution of Mr. Vivek Ashok Kumar Patel to the Company has approved to change his remuneration not exceeding Rs. 2,00,000 per month w.e.f., 11/09/2025 at their meeting held on 11/09/2025 subject to the approval of members on the terms and conditions as set out in this resolution.

In compliance with the provisions of 152, 196 and 197 read with schedule V of the Companies Act, 2013 and rules made there under change in remuneration of Mr. Vivek Ashok Kumar Patel as specified above is now being placed before the Members for their approval.

Notwithstanding anything to the contrary herein contained, where in any financial year during the currency of the tenure of the above mention Directors, the Company has no profits or its profits are inadequate, the Company will pay remuneration to him by way of Salary, Benefits, Perquisites and Allowances, Commission and Incentive Remuneration as specified above in accordance with applicable law as the minimum remuneration.

Except Mr. Vivek Ashok Kumar Patel and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

Disclosures as required to be made to the members for payment of remuneration in case of inadequacy of profits in accordance with the provisions of Companies Act, 2013 and schedule V is set out below:

1.	Basic Salary	Not Exceeding Rs. 2,00,000 per month with such increases as may be determined by the Board from time to time as per the rules of the Company.
2.	Incentive and Variable Pay	As per the Policy of the Company
3.	Perquisites	As per the Policy of the Company
4.	Retirement benefits	Payable in accordance with the Rules of the Company and the Fund.
Such other allowances, perquisites, amenities, facilities and benefits as per the Rules of the Company as applicable to the Non-Executive Director and as may be permitted and approved by the Board of Directors to be paid to the Non-Executive Director		

1. General Information:

1.	Nature of Industry	Engaged in Manufacturing and Trading of Pharmaceutical Products
2.	Date or expected date of commencement of commercial production	Company is operating since the day of its Incorporation
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	Not Applicable
4.	Financial performance based on given indicators	In the Financial year 2024-25, company has reported Turnover of Rs. 16,00,18,000 & has reported Net Profit after Tax of Rs. 2,50,09,000
5.	Foreign Investments or collaborations, if any	Not Applicable

2. Information about the appointee:

1.	Background details	As per Explanatory Statement attached to this Notice
2.	Past remuneration	Rs. 52,500 p.m.
3.	Recognition and awards	Nil
4.	Job profile and his sustainability	As per Explanatory Statement attached to this Notice
5.	Remuneration proposed	As per Explanatory Statement attached to this Notice
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration of Mr. Vivek Ashok Kumar Patel is comparable to that drawn by the peers in the similar capacity in the industry and is commensurate with the size of the Company and diverse nature of its business
7.	Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any	Not related to any of the Directors and KMP of the Company

3. Other Information:

1.	Reasons of loss or inadequate profits	The Company is expected to achieve adequate profits. However, in case due to any uncertain event if company fails to achieve adequate profits it is desirable to take approval of shareholders as part of good corporate governance practice.
2.	Steps taken or proposed to be taken for improvement	The Company will take significant steps for the overall growth and development in case of inadequate profits.
3.	Expected increase in productivity and profits in measurable terms	The Company is expected to grow in coming years and directors of the Company plan to continue to tread the path of optimum utilization of resources resulting in increase in productivity, profit and overall growth.

Details of Directors seeking appointment/re-appointment at the Annual General Meeting Pursuant to Secretarial Standard on General Meetings (SS-2) is annexed and Marked as Annexure-1 to this Notice

The Board recommends the Special resolution set out in Item No. 9 for approval of Members.

Item No.:10

Board of director proposed to appoint Mr. Arun Das (DIN: 09657537) as an Independent Director of the company in its meeting held on 11/09/2025.

Accordingly, the Company has received a notice from a member proposing candidature of Mr. Arun Das (DIN: 09657537), for the office of Director in terms of Section 160 of the Companies Act, 2013. Mr. Arun Das (DIN: 09657537) has also given a declaration to the company that he meets criteria of independence as prescribed under Section 149 (6) of the Companies Act, 2013 read with Rule 5 of Companies (Appointment & Qualification of Directors) Rules, 2014.

Brief Profile of Mr. Arun Das (DIN: 09657537):

Mr. Arun Das is Sole Proprietor of the Firm namely M/s. Arun Das & Associates, Company Secretaries.

He is well versed in managing company secretarial functions and ensuring compliance with statutory provisions under companies act/ other statutes, Intellectual Property laws and finance.

Copy of the draft letters for his appointment as Independent Director setting out the terms and conditions are available for inspection by members at the Registered Office of the Company between 11.00 A.M. to 1.00 P.M. on any working day upto the date of the Meeting.

The Company has also received the consent in writing to act as a Director, and an intimation that he is not disqualified under section 164(2) of the Companies Act, 2013.

Pursuant to Secretarial Standards-2 issued by the Institute of Company Secretaries of India, additional information about Mr. Arun Das is annexed in Annexure I to this Resolution.

Mr. Arun Das does not hold any shares/securities in the Company, either in her individual capacity or on a beneficial basis for any other person.

Except Mr. Arun Das and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

The Board recommends the ordinary resolution set out in Item No. 10 for approval of Members.

Item No.:11

Board of director proposed to appoint Mr. Mahipal Singh Chouhan (DIN: 08977710) as an independent director of the company in its meeting held on 11/09/2025.

Accordingly, the Company has received a notice from a member proposing candidature of Mr. Mahipal Singh Chouhan (DIN: 08977710), for the office of Director in terms of Section 160 of the Companies Act, 2013. Mr. Arun Das (DIN: 09657537) has also given a declaration to the company that he meets criteria of independence as prescribed under Section 149 (6) of the Companies Act, 2013 read with Rule 5 of Companies (Appointment & Qualification of Directors) Rules, 2014.

Brief Profile of Mr. Mahipal Singh Chouhan (DIN: 08977710)

Mr. Mahipal Singh Chouhan is currently working as Company Secretary and Compliance Officer at Rajshree Polypack Limited.

He is well versed in managing company secretarial functions and ensuring compliance with statutory provisions under companies act/ other statutes, Intellectual Property laws and finance.

Copy of the draft letters for his appointment as Independent Director setting out the terms and conditions are available for inspection by members at the Registered Office of the Company between 11.00 A.M. to 1.00 P.M. on any working day upto the date of the Meeting.

The Company has also received the consent in writing to act as a Director, and an intimation that he is not disqualified under section 164(2) of the Companies Act, 2013.

Pursuant to Secretarial Standards-2 issued by the Institute of Company Secretaries of India, additional information about Mr. Mahipal Singh Chouhan is annexed in Annexure I to this Resolution.

Mr. Mahipal Singh Chouhan does not hold any shares/securities in the Company, either in her individual capacity or on a beneficial basis for any other person.

Except Mr. Mahipal Singh Chouhan and his relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

The Board recommends the ordinary resolution set out in Item No. 11 for approval of Members.

Item No.: 12

Board of director proposed to appoint Ms. Shruti Gupta (DIN: 10310259) as an independent director of the company in its meeting held on 11/09/2025.

Accordingly, the Company has received a notice from a member proposing candidature of Ms. Shruti Gupta (DIN: 10310259), for the office of Director in terms of Section 160 of the Companies Act, 2013. Ms. Shruti Gupta (DIN: 10310259) has also given a declaration to the company that She meets criteria of independence as prescribed under Section 149 (6) of the Companies Act, 2013 read with Rule 5 of Companies (Appointment & Qualification of Directors) Rules, 2014.

Brief Profile of Ms. Shruti Gupta (DIN:10310259):

Ms. Shruti Gupta is currently working as Company Secretary and Compliance Officer at Western Overseas Study Abroad Private Limited.

She is competent, dynamic and qualified Company Secretary from The Institute of Company Secretaries of India; accented with latest trends and advancements of the field/ company laws and determination to carve a successful career in the industry.

She is well versed in managing company secretarial functions and ensuring compliance with statutory provisions under companies act/ other statutes. Good knowledge of conducting Board/ Committee/ General Meetings, compliances with Company Law requirements & Listing requirement and drafting required documents.

She is skilled in conducting board of Directors Meeting, Executive Committee Meeting as required under Companies Act involving issuance of notices, drafting agenda, recording minutes & preparing annual reports. Adroit in preparing & filing necessary documents, registers, forms & returns as required under the statutory acts.

She is focused and hardworking professional equipped with thorough knowledge and technical understanding coupled with an analytic bent of mind and confident to take challenging assignments. Ability to work accurately and quickly prioritize, coordinate & consolidate tasks with excellent communication, interpersonal, time management and presentation skills.

Copy of the draft letters for her appointment as Independent Director setting out the terms and conditions are available for inspection by members at the Registered Office of the Company between 11.00 A.M. to 1.00 P.M. on any working day upto the date of the Meeting.

The Company has also received the consent in writing to act as a Director, and an intimation that he is not disqualified under section 164(2) of the Companies Act, 2013.

Pursuant to Secretarial Standards-2 issued by the Institute of Company Secretaries of India, additional information about Ms. Shruti Gupta is annexed in Annexure I to this Resolution.

Ms. Shruti Gupta does not hold any shares/securities in the Company, either in her individual capacity or on a beneficial basis for any other person.

Except Ms. Shruti Gupta and her relatives, none of the other Directors and Key Managerial Personnel of the Company, or their relatives, are concerned or interested, financially or otherwise in this resolution.

The Board recommends the ordinary resolution set out in Item No. 12 for approval of Members.

Item No. 13

The Authorised Share Capital of the company as reflected in the Memorandum and Articles of Association as on date is Rs. 6,00,00,000 (Rupees Six Crore Only) divided into 60,00,000 (Sixty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten Only).

In view of the further requirement of the fund, the Authorised Share Capital of the Company needs to be increased from 6,00,00,000 (Rupees Six Crore Only) divided into 60,00,000 (Sixty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 8,00,00,000 (Rupees Eight Crore Only) divided into 80,00,000 (Eighty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten Only) by creation of additional 20,00,000 (Twenty Lakhs only) Equity Shares of Rs. 10/- each ranking pari passu in all respect with the existing Equity Shares.

Consequent to the increase of Authorised Share Capital, the Authorised Share Capital Clause contained in Clause 5 of the Memorandum of Association of the Company need to be altered as indicated in Resolution No.13 contained in the Notice convening the AGM.

A copy of the Memorandum and Articles of Association together with the proposed alterations is available for inspection by the Members at the Registered Office of the Company between 11:00 a.m to 2:00 p.m on all working days from the date hereof up to the date of the Meeting.

None of the Directors or Key Managerial Personnel of the Company or the relatives thereof are concerned or interested in this resolution except to the extent of their shareholding in the Company.

The Board recommends the Ordinary resolution set out in Item No. 13 for approval of Members.

Item No.14

The members know that the Company is engaged in the business of nutraceutical and related Products. The Board of Directors of the Company has decided to raise funds for Working Capital Requirements, General Corporate Purpose, Public Issue Expenses etc., in their board meeting held on 11/09/2025.

The Board of Directors proposing to issue up to 19,20,000 equity shares of face value of Rs. 10/- each at a price as may be decided by the Board of Directors of Company by way of initial public offer and get the equity shares listed on stock exchange.

Your Company seeks consent by a special resolution pursuant to the provisions of Section 62(1)(c) of the Companies Act, 2013 for further issue of equity shares as described above. Members are aware that the Company has planned to increase its business as a part of development and expansion. For that the Company needs more funds and the Board of Directors has planned to expand the capital base of the Company. The Board of Directors, therefore propose that the further Share Capital of the Company shall be increased and such share capital shall be increased by not more than 19,20,000 equity shares (Twenty Lakh Only) at a price as may be determined by the board of directors of the Company to such person or persons, who may or may not be the members of the Company and as the Board may at its sole discretion decide, including one or more of the members, Directors, their friends, relatives and associates, foreign/ resident investors, financial institutions, venture capital funds, public financial institutions, banks, multilateral and bilateral development financial institutions, insurance company(ies), provident funds, pension funds, national investment funds, foreign institutional investors, foreign venture capital investors, Indian and/or multilateral financial institutions, mutual funds, Non Resident Indians, employees and/or workers of the Company or its subsidiaries, in or out of India, Indian public, bodies corporate, any other company/companies, private or public or other body corporate(s) or entities whether incorporated or not, authorities and such other persons in one or more combinations thereof and/or any other categories of investors, whether they be holders of equity shares of the Company or not, and/or through issue of offer documents ("Initial Public Offer") / Allotment regulations of SEBI, through the Fixed Issue or Book Building Process, in one or more tranches and in the manner, and on the terms and conditions, as the Board may in its absolute sole discretion, decide including the price at which the equity shares are to be issued, at par or at premium and for cash and the decision to determine the category or categories of investors to whom the offer, issue and allotment/transfer shall be made to the exclusion of all other categories of investors on such terms and conditions as may be finalized by the Board and that the Board may finalize all matters incidental thereto as it may in its absolute discretion think fit.

None of the Directors or Key Managerial Personnel of the Company or the relatives thereof are concerned or interested in this resolution except to the extent of their shareholding in the Company.

The Board recommends the Special resolution set out in Item No. 14 for approval of Members.

For and on Behalf of the Board of Directors of

ACCRETION NUTRAVEDA LIMITED

Harshad Nanubhai Rathod

Director

DIN: 09108392

Mayur Popatlal Sojitra

Director

DIN: 09108404

Place: Ahmedabad

Date: 11/09/2025

Annexure I

Details of Directors seeking appointment/re-appointment at the 1st Annual General Meeting (Pursuant to Secretarial Standard on General Meetings (SS-2)):

Name of the Director	Arun Dash	Mahipal Singh Chouhan	Shruti Gupta	Vivek Ashok Kumar Patel	Mayur Popattal Sojitra	Hardik Mukundbhai Prajapati	Harshad Nanubhai Rathod	Paraskumar Vinubhai Parmar	Ankurkumar Shantilal Patel
DIN	09657537	08977710	10310259	09130357	09108404	09108403	09108392	10952040	09130391
Date of Birth	12/06/1976	05/03/1993	26/02/1991	05/12/1987	30/07/1987	09/12/1987	11/06/1986	17/08/1988	16/11/1986
Nationality	Indian	Indian	Indian	Indian	Indian	Indian	Indian	Indian	Indian
Age	49 Years	32 Years	34 Years	37 Years	37 Years	37 Years	38 Years	37 Years	38 Years
Qualifications	Company Secretary, LLB, MBA	Company Secretary, CMA, LLB,	Company Secretary, BBA	Bachelor in Pharmacy, MBA (Pharma)	Bachelor in Pharmacy, MBA (Pharma)	Master in Pharmacy	Bachelor in Pharmacy	Master in Pharmacy	Bachelor in Pharmacy
Experience (including expertise in specific functional area) / Brief Resume	Experience of approximately 20+ Years in Secretarial and Legal matters	Well versed with Companies Act, 2013 and SEBI Listing Regulation is having professional expertise in the said field of	More than 7 years' Experience in Secretarial and Legal Compliance for both listed and unlisted companies	He holds Bachelor of Pharmacy degree from LJP Ahmadabad. He has diversified experience in both production as well as marketing field of the	He holds Bachelor of Pharmacy degree from Gujarat University. An Honour MBA (International Business) from a prestigious university (University of Greenwich, London) from	He holds Bachelor of Pharmacy degree from LJP Ahmadabad. He is having more than 14 years of Pharmaceutical Production Experience.	He has done bachelor in Pharmacy from Gujarat University and MBA from Madhyanchal professional university, Bhopal. Harshad has altogether working experience of	He holds a Bachelor of Pharmacy (B.Pharm) from Gujarat University, Ahmedabad, and a Master's degree in International Business (M.A.) from the University	He holds a Bachelor of Pharmacy from L.J. Pharmacy College and a Master of Pharmacy in Ayurveda , bringing strong expertise in

Terms and Conditions of Appointment alongwith details of remuneration including sitting fees	Appointed as an Independent Director of the Company and will be paid sitting fees for attending Board and Committee meetings of the Company	Appointed as an Independent Director of the Company and will be paid sitting fees for attending Board and Committee meetings	Appointed as an Independent Director of the Company and will be paid sitting fees for attending Board and Committee meetings of the Company	industry since last 14 years.	UK helped him to build the strong business acumen. Furthermore, having had worked in Pharmaceutical Industries since last 12 years has given him vision to expand for the regulatory market in pharmaceutical industry.		Pharmaceutical sector more than 14 years. Currently, He Handles new development, regulatory work and Finance in the company	of Greenwich, London. His academic background and industry exposure enable him to contribute effectively to the company's growth and innovation in the nutraceutical and pharmaceutical space.	research, product development, and operational leadership. he has over 15 years of experience in the Herbal, Nutraceutical, and Ayurvedic industry.

	during his tenure.	of the Company during his tenure.	during his tenure.	during his tenure.				
Remuneration last drawn by such person, if applicable	Not Applicable	Not Applicable	Not Applicable	Rs. 52,500 per month	Rs. 52,500 per month	Rs. 52,500 per month	Rs. 80,000 per month	Rs. 80,000 per month
Date of first appointment on the Board	Not Applicable	Not Applicable	Not Applicable	31/03/2021	16/03/2021	16/03/2021	17/02/2025	31/03/2021
Shareholding in the Company including shareholding as a beneficial owner as on March 31, 2025	Nil	Nil	Nil	63,050 Equity Shares of Rs. 10 each amounting to Rs. 6,30,500 in the total paid up shareholding of the Company	63,050 Equity Shares of Rs. 10 each amounting to Rs. 6,30,500 in the total paid up shareholding of the Company	63,050 Equity Shares of Rs. 10 each amounting to Rs. 6,30,500 in the total paid up shareholding of the Company	97,400 Equity Shares of Rs. 10 each amounting to Rs. 9,74,000 in the total paid up shareholding of the Company	97,400 Equity Shares of Rs. 10 each amounting to Rs. 9,74,000 in the total paid up shareholding of the Company
Relationship with other Directors / Key Managerial Personnel	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Number of meetings of	Not Applicable	Not Applicable	Not Applicable	11(Eleven)	11(Eleven)	11(Eleven)	5 (Five)	11 (Eleven)

on March 31, 2025				of Accretion Pharmaceuticals Limited	of Accretion Pharmaceuticals Limited	Stakeholders Relationship Committee and Corporate Social Responsibility Corporate Social Responsibility of Accretion Pharmaceuticals Limited	
-------------------	--	--	--	--------------------------------------	--------------------------------------	--	--

Annexure II

Membership / Chairmanship of Committees of other Boards as on March 31, 2025

Name: Arun Dash			
Name of the Company	Audit Committee	Stakeholders' Relationship Committee	Nomination and Remuneration Committee
Arjun Jewellers Limited	Member	Member	Member
			Member
			N.A.

Name: Mahipal Singh Chouhan			
Name of the Company	Audit Committee	Stakeholders' Relationship Committee	Nomination and Remuneration Committee
Navigant Corporate Advisors Limited	Member	Chairman	Member
Arjun Jewellers Limited	Member	Member	Member
			N.A.
			N.A.

Name: Shruti Gupta					
Name of the Company	Audit Committee	Stakeholders' Relationship Committee	Nomination and Remuneration Committee	CSR Committee	
Super Fine Knitters Limited	Chairman	Chairman	Chairman	N.A.	
Garg Furnace limited	Member	Member	Member	N.A.	
Arjun Jewellers Limited	N.A.	Chairman	Member	Member	
Checkpoint Trends Limited	Member	Member	Member	N.A.	
Technocraft Ventures Limited	Member	N.A.	N.A.	Chairman	
Super Fine Knitters Limited	Chairman	Chairman	Chairman	N.A.	

PROXY FORM

4th Annual General Meeting of Accretion Nutraveda Limited

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of Member(s) (IN BLOCK LETTERS)			
Registered Address (IN BLOCK LETTERS)			
No. of Shares Held		Folio No.	
E-Mail Id			

I/We, being the member(s) of _____ Equity shares of Accretion Nutraveda Limited, hereby appoint:

Name			
Address			
E-Mail Id		Signature	

or failing him

Name			
Address			
E-Mail Id		Signature	

or failing him

Name			
Address			
E-Mail Id		Signature	

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 4th Annual General Meeting of the Company, to be held on Thursday, 11th September, 2025 at 04:00 P.M. at registered office of the company situated at 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta- Sanand, Ahmedabad-382213, Gujarat, India and at any adjournment thereof in respect of such resolutions as are indicated below:

Ordinary Business

1.	Adoption of Audited Financial Statement, Reports of the Board of Directors and Auditors thereon for the financial year ended 31st March, 2025 (Ordinary Resolution)
2.	Appointment of Statutory Auditors of the Company
3.	To appoint a director in place of Mr. Harshad Nanubhai Rathod (DIN: 09108392), who retires by rotation and being eligible, offers himself for re-appointment.

Special Business

4.	Regularization of Appointment of Mr. Paraskumar Vinubhai Parmar (DIN: 10952040) As an Executive Director
5.	Change in designation of Mr. Mayur Popatlal Sojitra (DIN: 09108404) as Managing Director of the company and Revision in terms of Remuneration.
6.	Change in designation of Mr. Ankurkumar Shantilal Patel (DIN: 09130391) as Whole-time Director of the company and Revision in terms of Remuneration.
7.	Revision in terms of Appointment and Remuneration of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403) as Non-Executive Director of the company.
8.	Revision in terms of Appointment and Remuneration of Mr. Harshad Nanubhai Rathod (DIN: 09108392) as Non-Executive Director of the company
9.	Revision in terms of Appointment and Remuneration of Mr. Vivek Ashok Kumar Patel (DIN: 09130357) as Non-Executive Director of the company.
10.	To consider and approve the appointment of Mr. Arun Dash as Professional Independent Director of the Company
11.	To consider and approve the appointment of Mr. Mahipal Singh Chouhan as Professional Independent Director of the Company.
12.	To consider and approve the appointment of Ms. Shruti Gupta as Professional Independent Director of the Company
13.	To consider and approve Increase in Authorised capital of the Company
14.	To consider and approve Public issue

Signed this..... day of _____, 2025

Signature of shareholder

Signature of shareholder

Affix
Rs.1
Revenue
Stamp

Notes:

This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company not less than 48 hours before the commencement of the Meeting.

ATTENDANCE SLIP

4th Annual General Meeting of Accretion Nutraveda Limited

Name of Shareholder	
No. of Equity Shares Held	
Folio No.	

I hereby record my presence at the 4th Annual General Meeting of Members of Accretion Nutraveda Limited, held Thursday, 11th September, 2025 at 04:00 P.M. at registered office of the company situated at 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta- Sanand, Ahmedabad-382213, Gujarat, India

Name of Member / Proxy/Authorized Representative
(IN BLOCK LETTERS)

Signature of Member / Proxy/Authorised Representative


Note:

1. Please fill up this attendance Slip and hand it over at the entrance of the meeting hall. Members are requested to bring their copies of the Annual Report at the AGM.

Route map to the venue of the 4th Annual General Meeting

Venue: 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta- Sanand, Ahmedabad-382213, Gujarat, India

Landmark: Accretion Nutraveda Limited



CORPORATE INFORMATION

BOARD OF DIRECTORS

Harshad Nanubhai Rathod:	Director
Mayur Popatlal Sojitra:	Director
Ankurkumar Shantilal Patel:	Director
Paraskumar Vinubhai Parmar:	Director
Vivek Ashokkumar Patel:	Director
Hardik Mukundbhai Prajapati:	Director

COMPANY SECRETARY

Payal Hareshbhai Kotadiya (Appointed w.e.f. 06 September, 2025)

STATUTORY AUDITOR

M/s. V S S B & Associates, Chartered Accountants
A/912, 9th Floor, Ratnaakar Nine Square,
Opp. ITC Narmada Hotel, Vastrapur, Ahmedabad - 380015

SECRETARIAL AUDITOR

M/s. Sakhiya & Co., Practicing Company Secretaries
Office - 502, RK Empire, Opp. Sanskar Heights,
Nr. Mavdi Chowkdi, 150 Feet Ring Road,
Rajkot-360 004, Gujarat, India.

BANKER

INDIAN BANK
Paldi Branch

REGISTRAR & TRANSFER AGENT

KFIN TECHNOLOGIES LIMITED
Selenium Tower-B,
Plot No. 31 & 32, Financial District,
Nanakramguda, Hyderabad - 500 032
Toll free No: 18003094001
Email Id: cinward.ris@kfintech.com
Website: www.kfintech.com

REGISTERED OFFICE

ACCRETION NUTRAVEDA LIMITED
CIN: U24290GJ2021PLC121216
27 Xcelon Industrial Park-1, Vasna-Chacharwadi,
Ta- Sanand, Ahmedabad, Gujarat, India, 382213
Mobile: +91-9904366177
E-Mail: compliance@accretionnutraveda.com
Website: accretionnutraveda.com



www.accretionnutraveda.com

NUTRACEUTICALS | HERBAL

Office: 27, Xcelon Industrial Park-1, Behind intas Pharmaceuticals,
Vasna-chacharwadi, Ahmedabad – 382213 Gujarat, India
+91 99043 66177 | compliance@accretionnutraveda.com